REVIEW article

Front. Genet., 23 March 2022

Sec. Human and Medical Genomics

Volume 13 - 2022 | https://doi.org/10.3389/fgene.2022.861241

The Genomic Architecture of Hidradenitis Suppurativa—A Systematic Review

  • 1. Center for Molecular Medicine and Biobanking, University of Malta, Msida, Malta

  • 2. Department of Pathology, Faculty of Medicine and Surgery, University of Malta, Msida, Malta

  • 3. Department of Dermatology, Mater Dei Hospital, Msida, Malta

  • 4. Department of Pathology, Mater Dei Hospital, Msida, Malta

Abstract

Hidradenitis suppurativa is a chronic, suppurative condition of the pilosebaceous unit manifesting as painful nodules, abscesses, and sinus tracts mostly in, but not limited to, intertriginous skin. Great strides have been made at elucidating the pathophysiology of hidradenitis suppurativa, which appears to be the product of hyperkeratinization and inflammation brought about by environmental factors and a genetic predisposition. The identification of familial hidradenitis suppurativa has sparked research aimed at identifying underlying pathogenic variants in patients who harbor them. The objective of this review is to provide a broad overview of the role of genetics in various aspects of hidradenitis suppurativa, specifically the pathophysiology, diagnosis, and clinical application.

Introduction

Hidradenitis suppurativa (HS) is a chronic, suppurative disorder characterized by inflammation and hyperkeratinization at the pilosebaceous unit (PSU). The condition manifests as tender nodules, draining abscesses and sinuses mostly in (but not limited to) intertriginous skin (von Laffert et al., 2011; ). The latest estimate of overall HS prevalence is 0.4% (95%CI, 0.26–0.63%) (Jfri et al., 2021). HS can arise as an isolated condition, in a syndromic form or in the setting of other cutaneous conditions (for example Dowling-Degos Disease). The pathophysiology of HS is complex and is strongly determined by environmental and lifestyle factors such as smoking and obesity. These factors interact with specific physical triggers, namely friction, sweat, increased temperature, and changes in the cutaneous microbiome to drive disease risk (Mintoff et al., 2021a).

HS has an underlying genetic etiology. The link between HS and a genetic predisposition has long been suspected. In the 1980s Fitzsimmons and Guilbert published evidence in favor of autosomal dominant or familial HS (fHS) (; ; ); however the causative gene remained elusive. Initial studies performed by Gao et al. suggested a possible HS locus at 1p21.1-1q25.3 (). Based on these findings, linkage analysis was performed on HS-patients with a strong family history however, the results obtained failed to identify the causative locus (Saleh Al-Ali et al., 2010). Following the advent of whole exome sequencing (WES), Gao et al later described the c.210_211delAG NCSTN variant which segregated with disease in multiple family members affected by HS (Liu et al., 2011). Since then, several other investigators have provided evidence supporting a monogenic etiology in fHS, mostly involving loci encoding proteins of the γ-secretase complex (GSC) (OMIM #142690, #613736, #613737). These initial discoveries have fueled a strong drive to explore the role of genetic susceptibility in HS with the aim of better characterizing the pathophysiology of the disease.

The mechanisms and extent to which the combination of genomic and non-genomic factors determine disease manifestation, its phenotype and response to therapy are not fully understood. The increasing availability and affordability of genomic sequencing in both clinical and research settings, as well as more robust methods of interrogating the human genome has resulted in a surge of genetic data on HS. This genetic data is supported by in vitro and in vivo functional studies in a minority of cases. Nevertheless, a comprehensive understanding of the role of rare vs. common genetic factors that drive HS is lacking.

This systematic review aims to compile, analyze and present the extant literature pertaining to the genetic architecture of HS. Specifically, we aim to 1) comprehensively describe genetic variants that have been associated with HS phenotypes 2) evaluate the impact of selected missense variants on protein structure and stability using in-silico tools 3) explore genotype-phenotype associations and 4) discuss HS genetics in the context of disease subtypes.

Methods

Literature Search

A systematic literature search pertaining to hidradenitis suppurativa and genetic variation was conducted in PubMed/MEDLINE, Science Direct and Google Scholar databases. A comprehensive search strategy was based on the following combinations of free text keywords and Medical Subject Heading (MeSH) terms: “hidradenitis”, “suppurativa”, “acne”, “inversa”, “genetic”, “familial”, “secretase”, “nicastrin”, “NCSTN”, “PSENEN”, “presenilin”, “PSEN”, “APH”, “NOD2”, “PSTPIP1”, “MEFV”, “Syndrome”, “PASH”, “PAPASH”, “Pyoderma”, “SAPHO”, “PASS”, “Dowling-Degos”, “Mediterranean”. The Boolean operators used were “AND” and “OR”. The search covered articles published between January 1980 and January 2022, and was restricted to articles published in the English, Italian and Spanish languages. Furthermore, handsearching and citation review of relevant studies was also conducted to identify studies that were not captured by the electronic database search. Published original studies investigating the genetics of HS in its isolated or syndromic forms through both targeted and untargeted genomic approaches were eligible for inclusion. We excluded studies with 1) absent genetic data 2) duplicate data pertaining to the same proband in separate publications 3) conference proceedings, reviews, editorial letters or comments and 4) studies not directly investigating the association of specific genes with HS phenotypes.

Data Extraction

Articles identified from the literature search were screened for duplicates. All studies deemed to be potentially eligible for inclusion were reviewed and data extracted by the investigators. Any discrepancies were resolved by consensus.

The following information was extracted from each eligible article 1) primary author and year of publication 2) locus, the specific genetic variant identified and segregation data when available 3) age at presentation of first lesion 4) primary anatomic sites affected and 5) data on comorbid risk factors, specifically obesity and smoking status.

Data Analysis

Identified variants were categorized as missense, nonsense, frameshift indels, splice-site and non-coding regions according to their effect on translation. VarSeq software (Golden Helix) was used for variant interpretation and annotation (Kopanos et al., 2019). Variant pathogenicity was classified according to guidelines from the American College of Medical Genetics/Association for Molecular Pathology (ACMG/AMP) (Richards et al., 2015). These guidelines standardize variant classification by stratification into five categories (pathogenic, likely pathogenic, uncertain significance, likely benign, benign) based on a combination of computational, population, functional and segregation data. Rare variants were considered to be of uncertain significance (VUS) if there is limited or contradictory clinical or functional evidence for pathogenicity. The Human Gene Mutation Database, (HGMD), dbSNP and ClinVar databases (ncbi.nlm.nih.gov/clinvar/) were also interrogated to identify any respective studies and ontologies. To explore genotype-phenotype associations, variants in the GSC genes were considered as an aggregate category and contrasted against variants in genes not forming part of this complex.

Protein Structure Analysis and Molecular Modelling

The impact of missense variants on protein structure was evaluated through molecular modelling. The DynaMut webserver was used to predict the effects of amino acid substitutions on protein stability, flexibility and to analyze interactions amongst amino acid residues (Rodrigues et al., 2018). The predicted change in stability between the wild type and variant structures derived from SDM, DUET, and mCSM algorithms is reported as ΔΔG in kcal/mol, with negative values indicative of destabilizing variants. Dynamut also reports vibrational entropy changes (ΔΔSVib in kcal mol−1K−1) calculated by ENCoM using normal-mode analysis to depict the substitution’s effect on structure flexibility or rigidity. To further categorize the structural impact of missense variants, the Missense3D and HOPE webservers were used. Missense3D assesses 17 different structural features that are essential for protein conformation and stability, such as stearic clashes and disallowed phi/psi angles (Venselaar et al., 2010; Ittisoponpisan et al., 2019). A comprehensive graphical summary of identified GSC variants was generated using ProteinPaint (Zhou C et al., 2016).

Statistics

The characteristics of the cohort are summarized using descriptive statistics. Normality of age at first lesion was assessed by the Shapiro–Wilk and Kolmogorov-Smirnoff tests. This exhibited a skewed non-normal distribution; non-parametric statistics with medians and interquartile ranges are presented. To compare differences in quantitative variables between two categories, the independent-samples Mann–Whitney U test was applied. The chi-square test was used to compare categorical variables. A p-value of <0.05 was considered statistically significant.

Results

In total, the literature search identified 88 published variants implicated in HS. Approximately 83% of published variants involve the four genes encoding protein subunits of the multimeric GSC (NCSTN 54.5%, PSENEN 24%, PSEN 3.4% and APH 1%) (Figure 1). The remaining variants localized to PSTPIP1, MEFV, NLRP3, IL1RN, NOD2 and POFUT loci, which have been variably associated with non-syndromic forms of HS. A summary of the identified variants, their pathogenicity classifiers and phenotypes are provided in Table 1. The reported median age at first lesion was 17 years (min 10 years—max 67 years). The axillae and groin were the most frequently reported affected sites. Clear segregation with the HS phenotype was documented by 78% of reports. The identified variants were classified as pathogenic or likely pathogenic in 66% of cases, and as VUS or VUS leaning pathogenic in 18% of cases according to the ACMG-AMP consensus criteria. At the protein level, variants were classified as missense (29.5%), nonsense (24%), frameshift indels (28.4%), splice donor/acceptor site (15.9%) and in non-coding regions (2.3%). Lifestyle factors that associate with HS predisposition and outcome, such as obesity and smoking status were inconsistently reported in the literature.

FIGURE 1

TABLE 1

GeneExon/IntronVariantProteinACMG classificationVariant SegregationAge of 1st Lesion in the ProbandInvolved SkinObesity and smoking StatusGroup
NCSTN1NM_015331.3:c.38delGp.Gly13GlufsTer15Likely pathogenicSporadic10Axilla, inguinal, glutealNot SpecifiedVural et al. (2021)
NCSTN2NM_015331.3:c.97G > Ap.Gly33ArgUncertain significance with some pathogenic evidenceYesNot SpecifiedAxilla, neck, trunk, axilla, gluteal, extremityNot specifiedTakeichi et al. (2020)
NCSTN2NM_015331.3:c.182G > Tp.Gly61ValUncertain significance leaning pathogenicYes17Not SpecifiedObese, Non-smoker
NCSTN3NM_015331.3:c.210_211delAGp.Val72TyrfsTer16PathogenicYesNot specifiedAbdomen, back, glutealNot SpecifiedLiu et al. (2011)
NCSTN3NM_015331.3:c.218delCp.Pro93LeufsTer15PathogenicYes24Face, Neck, Back, Gluteal, GroinNot specifiedWu et al. (2018)
NCSTN3NM_015331.3:c.223G > Ap.Val75lleBenignYes16Face, Neck, Mons pubis, GenitalsNot SpecifiedZhang et al. (2013)
NCSTN3NM_015331.3:c.278del *p.Pro93LeufsTer15PathogenicSporadic40Neck, Back, Axilla, GlutealNot obeseLi et al. (2018)
NCSTN4NM_015331.3:c.344_351del p.Thr115AsnfsTer20PathogenicProband adopted11Not SpecifiedNot obese
NCSTN4NM_015331.3:c.349C > Tp.Arg117TerPathogenicYesNot SpecifiedNot SpecifiedNot specifiedWang et al. (2010)
NCSTN5NM_015331.3:c.450_459delp.Ser151GlnfsTer48PathogenicYes11Axilla, back, glutealNot specifiedWu et al. (2020)
NCSTN5NM_015331.3:c.477C > Ap.Cys159TerPathogenicYes17Neck, Axillae, Gluteal, Popliteal fossaeNot obeseXiao et al. (2016)
NCSTN5NM_015331.3:c.487delCp.Gln163SerfsTer39Likely PathogenicYesNot SpecifiedAxillary, inguinal and perineal foldNot obeseMiskinyte et al. (2012)
NCSTN5NM_015331.3:c.497C > Ap.Ser166TerLikely pathogenicYes14Axillae, buttocks, groin and neckNot SpecifiedMa et al. (2014)
NCSTN5NM_015331.3:c.553G > Ap.Asp185AsnUncertain SignificanceSporadic13Axillae, chest, groin, buttocksSmoker, ObesePink et al. (2012)
NCSTNExon5/intron5 Donor splice siteNM_015331.3:c.582+1delGNot applicablePathogenicYesNot SpecifiedNeck and perineal regionNot SpecifiedNomura et al. (2013)
NCSTN6NM_015331.3:c.617C > Ap.Ser206TerPathogenicYes17Head, Face, Axilla, Groin, ButtocksNot obeseShi et al. (2018)
NCSTN6NM_015331.3:c.632C > Gp.Pro211ArgLikely PathogenicSporadic38Axilla, trunk, buttock, groinNot obeseLi et al. (2011)
NCSTN6NM_015331.3:c.647A > Cp.Gln216ProUncertain Significance leaning pathogenicYes18Neck, Axillae, buttocks, and groinNot specifiedZhang et al. (2013)
NCSTN6NM_015331.3:c.671_682delp.Val224_Thr227delLikely pathogenicYes13Axilla, Breast, Antecubital fossae, NeckNot obese, SmokerMintoff et al. (2021c)
NCSTN6NM_015331.3:c.686_687dupp.Cys230ProfsTer31PathogenicYesNot SpecifiedNot specifiedNot specifiedRatnamala et al. (2016)
NCSTN7NM_015331.3:c.751_752delp.Leu251ValfsTer2PathogenicYes13Axilla, groin, buttock, back, lower abdomen, jawNot SpecifiedZhang et al. (2021)
NCSTN8NM_015331.3:c.887A > Gp.Glu296GlyBenignYesNot SpecifiedNot specifiedNot specifiedXu et al. (2016)
NCSTN8NM_015331.3:c.944C > Tp.Ala315ValUncertain significance leaning pathogenicYes17Buttock, Groin, Face, Scalp, Axillae, BackNot specifiedZhang S et al. (2016)
NCSTN8NM_015331.3:c.996+1G > Ap.Glu333_Gln367delPathogenicNot SpecifiedNot specifiedNot SpecifiedNot SpecifiedPink et al. (2016)
NCSTNIntron 8NM_015331.3:c.996+7G > ANot ApplicableBenignSporadic35Axillae, Groin, ButtocksSmoker, ObesePink et al. (2012)
NCSTNExon 9/intron 9 donor splice siteNM_015331.3:c.1101+1G > ANot applicablePathogenicYes16Axillae, suprapubic area, groin, buttocks, thighs and neckSmoker, ObesePink et al. (2011)
NCSTNDonor Splice site of exon 9NM_015331.3:c.1101 + 10A > GNot ApplicableUncertain significanceSporadic16Axillae, Groin, Buttocks, GenitaliaSmoker, Not obesePink et al. (2012)
NCSTN11NM_015331.3:c.1229C > Tp.Ala410ValBenignSporadic32SevereNon-smoker, Not obeseLiu et al. (2016)
NCSTN11NM_015331.3:c.1258C > Tp.Gln420TerPathogenicYesNot specifiedNeck, HipNon-ObeseJiao et al. (2013)
NCSTN11NM_015331.3:c.1285C > Tp.Arg429TerPathogenicYes15Face, abdomen, limbs, GlutealNon-smokerNishimori et al. (2020)
NCSTN11NM_015331.3:c.1294C > Tp.Arg432TerPathogenicNot SpecifiedNot specifiedGluteal, Groin and PerineumNot obeseLin et al. (2021)
NCSTN11NM_015331.3:c.1300C > Tp.Arg434TerPathogenicYesPubertyAxillary, inguinal and perineal foldNon-ObeseMiskinyte et al. (2012)
NCSTN11NM_015331.3:c.1325_1326insGTTGTTCTGTAGTGGCp.Asp443LeufsTer6PathogenicNot SpecifiedNot SpecifiedNot SpecifiedNot SpecifiedPlenary Lectures, (2019)
NCSTNIntron 11 Splice donor siteNM_015331.3:c.1352+1G > ANot applicablePathogenicYesNot SpecifiedNot SpecifiedNot SpecifiedLiu et al. (2011)
NCSTNIntron 13 Splice siteNM_015331.3:c.1551+1G > Ap.Ala486_Thr517delPathogenicYesNot SpecifiedTypical and Atypical areasNot specifiedWang et al. (2010)
NCSTN13NM_015331.3:c.1534C > Tp.Gln512TerPathogenicNot specifiedNot SpecifiedNot SpecifiedNot specified
NCSTN14NM_015331.3:c.1555dupAp.Thr519AsnfsTer9PathogenicNot specified19Neck, axillae, back, upper chest, gluteal and buttocksNot specifiedQian et al. (2021)
NCSTN14NM_015331.3:c.1635C > G p.Tyr545TerPathogenicYes10Axillae, ChestNot specified
NCSTN15NM_015331.3:c.1695T > Gp.Tyr565TerLikely pathogenicYes26Neck, axillae, gluteal and groinsNot obeseLi et al. (2011)
NCSTN15NM_015331.3:c.1702C > Tp.Gln568TerPathogenicYes15Face, Neck, ButtocksNot specifiedNomura et al. (2014)
NCSTN15NM_015331.3:c.1727G > Tp.Gly576ValUncertain significance leaning pathogenicFamilial but not studied23Not specifiedNot obese, Non smoker
NCSTN15NM_015331.3:c.1747C > Tp.Arg583TerPathogenicYes25Inguinal, genitalNon obese, Non-smoker
NCSTN15NM_015331.3:c.1752delGp.Glu584AspfsTer44PathogenicYesNot specifiedTypical and atypical areasNot specifiedWang et al. (2010)
NCSTN15NM_015331.3:c.1768A > Gp.Ser590AlafsTer3Likely benignYesNot specifiedAxillary, inguinal and perineal foldNon-obeseMiskinyte et al. (2012)
NCSTN16NM_015331.3:c.1800_1801delTGp.Tyr600TerLikely pathogenicYesNot SpecifiedNot specifiedNot specifiedRatnamala et al. (2016)
NCSTN16NM_015331.3:c.1876C > Tp.Arg626TerPathogenicNot SpecifiedNot SpecifiedNot SpecifiedNot SpecifiedPlenary Lectures, (2019)
NCSTN16NM_015331.3:c.1912_1915delCAGTp.Ser638fsPathogenicYesBefore 20Axillary, Inguinal, Back, nape and auricular regionEx-Smoker, non-obeseVossen et al. (2020b)
NCSTN3′UTRNM_015331.3:c.2584_2585delCAReduced expressionPathogenic*SporadicNot specifiedGlutealNot SpecifiedXiao et al. (2018)
PSEN17NM_000021.4:c.725delCp.Pro242LeufsTer11PathogenicYesNot specifiedAxilla, groin and GlutealNot specifiedWang et al. (2010)
PSEN19NM_000021.4:c.953A > Gp.Glu318GlyLikely benignNot specifiedNot specifiedNot specifiedNot specifiedIngram et al. (2013)
PSEN111NM_000021.4:c.1167_1168insGAp.Gly390GlufsTer20PathogenicYes173Obese, smoker
PSENEN2NM_172341.4:c.13C > Tp.Arg3TerPathogenicYes11Not SpecifiedNot SpecifiedQian et al. (2021)
PSENEN2NM_172341.4:c.35T > A+p.Leu12TerPathogenicYesNot specifiedInguinal folds, GenitalsObese, smokerRalser et al. (2017)
PSENEN2NM_172341.4:c.43_56delp.Cys15ProfsTer101PathogenicYes54Axilla and buttocksNot obese (according to pictures) smoking history not specifiedKan et al. (2018)
PSENENSplice SiteNM_172341.4:c.62-1G > C +Not applicablePathogenicYesNot SpecifiedAxillae, inguinal folds, genitalsObese, SmokerRalser et al. (2017)
PSENENSplice SiteNM_172341.4:c.62-1G > T +Not applicablePathogenicNot specified16Axillae, Face and trunkNot obese, Smoking history not specifiedPeter et al. (2021)
PSENENSplice SiteNM_172341.4:c.66dup +p.Phe23ValfsTer98PathogenicSporadicNot specifiedNot specifiedNot specified
PSENEN3NM_172341.4:c.66delGp.Phe23LeufsTer46PathogenicYes16Nape, upper back and buttocksNot obese according to clinical photos, Smoking history not specifiedXiao et al. (2020)
PSENEN3NM_172341.4:c.66_67insGp.Phe23ValfsTer98PathogenicYes15Inframammary fold, axillae, groinNot obese, Non-smokerPink et al. (2011)
PSENEN3NM_172341.4:c.115C > T +p.Arg39TerPathogenicYesNot SpecifiedNot SpecifiedObese, SmokerRalser et al. (2017)
PSENENIntronicNM_172341.4:c.166+2T > C +Not applicablePathogenicYes13Not SpecifiedNot obese, Non-smoker
PSENENIntronicNM_172341.4:c.167–2A > G +Not applicablePathogenicYes15Face, neck, trunkNot specifiedZhou X et al. (2016)
PSENEN4NM_172341.4:c.168T > G +p.Tyr56TerPathogenicSporadicSecond decade“Flexural areas”Not SpecifiedPavlovsky et al. (2018)
PSENEN4NM_172341.4:c.194T > G +p.Leu65ArgPathogenicYesNot specifiedAxilla, Neck, PerineumNot SpecifiedLi et al. (2017), Zhou C et al. (2016)
PSENEN4NM_172341.4:c.228_229insCACC p.Ile77HisfsTer45PathogenicYes22Nape, Axilla, buttocksNot specifiedZhang et al. (2020)
PSENEN4NM_172341.4:c.229_230insCACCp.Ile77ThrfsTer45PathogenicNot specifiedNot SpecifiedNot SpecifiedNot specifiedZhou et al. (2021)
PSENEN4NM_172341.4:c.271delTp.Tyr91ThrfsTer54PathogenicNo Incomplete penetrance“Mean 15.15”Not SpecifiedNot SpecifiedTheut Riis et al. (2020)
PSENEN4NM_172341.4:c.279delCp.Phe94SerfsTer51PathogenicYesNot specifiedTypical and atypical”Not specifiedWang et al. (2010)
PSENENNM_172341.4:c.292delp.Leu98TrpfsTer47PathogenicNo Incomplete penetrance“MEAN15.5”Not SpecifiedNot SpecifiedTheut Riis et al. (2020)
PSENEN4NM_172341.4:c.304T > A+p.Ter102ArgxtTer50Likely pathogenicNot specified18Hurley 3Not-obese, non-smoker
PSENENSplice SiteNM_172341.4:g.1412T > C +Not applicablePathogenicYesNot SpecifiedAxillae, Inframammary region, inguinal foldsNon-smoker, obeseRalser et al. (2017)
APH1B5NM_031301.4:c.509A > Gp.His170ArgUncertain SignificanceIncomplete penetranceMean 15.5Typical and atypicalNot specifiedTheut Riis et al. (2020)
PSTPIP1Promotor regionENST00000558012.6:c.-413_-402dupCCTGCCTGCCTG Not applicableBenignNot specified15Hurley Stage IIINot specifiedVural et al. (2019)
PSTPIP111ENST00000558012.6:c.748G > C p.Glu250GlnLikely pathogenicSporadicNot specifiedDoes not look obese on pictures, Smoking history not specifiedKotzerke et al. (2021)
PSTPIP111ENST00000558012.6:c.764C > T$p.Thr255MetBenignNot Specified67Buttocks, HipsNot SpecifiedHieta et al. (2021)
PSTPIP110ENST00000558012.6:c.831G > T p.Glu277AspUncertain Significance leaning pathogenicNot specified14AxillaN/AMarzano et al. (2013)
PSTPIP114ENST00000558012.6:c.1034A > G p.Tyr345CysUncertain significanceYes18Axillae, GroinNot SpecifiedSaito et al. (2018)
PSTPIP115ENST00000558012.6:c.1213C > Tp.Arg405CysConflicting interpretation of pathogenicitySporadic27Sacrococcygeal region, Intergluteal folds, perineal regionNon-smoker/Not obese
POFUT14NM_015352.2:c.430-1G > A *Consensus splice site mutationPathogenicNot Specified23Groin and AxillaeNot Specified
MEFV10NM_000243.3:c.2177T > Cp.Val726AlaPathogenicYes18Back, thighs, groinNon-smoker Non-obeseJfri et al. (2020)
NLRP34ENST00000336119.8:c.2107C > A p.Gln703LysBenignNot specifiedNot specified (Age at diagnosis given)Face, trunk, lower extremities, axillary and inguinal folds, anogenital areaNot specifiedMarzano et al. (2014)
IL1RN4NM_000577.5:c.370G > Ap.Ala106ThrBenignNot specifiedNot specified (Age at diagnosis given)Face, trunk, lower extremities, axillary and inguinal folds, anogenital areaNot specifiedMarzano et al. (2014)
NOD28NM_001370466.1:c.2023C > T p.Arg675TrpBenignNot specifiedNot specified (Age at diagnosis given)Face, trunk, lower extremities, axillary and inguinal folds, anogenital areaNot specifiedMarzano et al. (2014)
NOD28NM_022162.3:c.2722G > C p.Gly908ArgBenignNot specifiedNot specified (Age at diagnosis given)Face, trunk, lower extremities, axillary and inguinal folds, anogenital areaNot specifiedMarzano et al. (2014)
NOD210NM_022162.3 c.2923C > Gp.Leu975ValUncertain significanceYes19Axilla, Inner thighsNon-smoker, non-obeseJfri et al. (2020)

A summary of described genetic variants, their protein effect, ACMG classification and phenotypic associations. *SAPHOPASH • PAPASH$PPHSF+HS-DDD.

No significant difference in the reported age at first lesion was identified between carriers of variants in GSC and other loci (17 vs. 19 years, p = 0.112). Similarly, no difference in age at first lesion between NCSTN variant carriers and non-NCSTN variant carriers was identified (17 vs. 18 years, p = 0.345). Carriers of pathogenic variants had a marginally lower age at first lesion than carriers of VUS or benign variants (16 vs. 18 years p = 0.048). A significantly higher proportion of pathogenic variants was located in GSC genes compared to other loci (74 vs. 26.7%, χ2 = 12.1, p = 0.001). As expected, variants that disrupt translation through nonsense, frameshift or splice-altering effects are more likely to be pathogenic than missense variants (91.4% vs. 8.6%, χ2 = 42.2, p < 0.01). No significant difference in obesity or smoking status was noted when probands carrying pathogenic variants were compared to those carrying non-pathogenic variants, although these parameters were inconstantly reported in the literature. No association between the primary anatomic sites involved by HS lesions and gene (NCSTN vs. non-NCSTN) or the ACMG pathogenicity classifier (pathogenic vs. non-pathogenic variants) was noted. Table 2 contrasts the salient clinical and genetic features between GSC variant carriers and non-carriers.

TABLE 2

GSC Genes (n = 73)Non-GSC Genes (n = 15)
Age of first lesion (years)Median (IQR)17 (9)19 (9)
Protein effectMissense17.8%86.7%
Nonsense28.8%0.0%
Frameshift indels34.2%0.0%
Splice site17.8%6.7%
UTR/non-coding1.4%6.7%
ACMG/AMP classificationPathogenic74.0%26.7%
VUS20.5%20.0%
Benign5.5%53.3%
SegregationSegregation79.7%60.0%
Sporadic15.3%40.0%
Incomplete Penetrance5.1%0.0%
% Obese32.3%0.0%
% Smokers50.0%0.0%

A comparison of the salient clinical and genetic findings between HS cases bearing variants in γ-secretase complex genes and HS cases with variants at other loci. All non-GSC genes (PSTPIP, MEFV, NOD2, IL1RN and NLRP3) that have been associated with HS subtypes are considered as an aggregate category.

Abbreviations GSC - γ-secretase complex. IQR, interquartile range; VUS, variants of uncertain significance; UTR, untranslated region.

For selected missense variants we explored the structural impacts of the substitution and assessed the change in ΔΔG and Δ vibrational entropy energy predictions between the wild-type and mutant structures. An overview of the findings is presented in Supplementary Table S1. Only five of 23 (21.73%) missense variants were predicted to exert conformationally deleterious effects as they impact critical structural residues (NCSTN p. Gly61Val, p. Gln216Pro, p. Glu296Gly, p. Gly576Val and APH p. His170Arg). Four of these variants have VUS/VUS leaning pathogenic classifications while the fifth (NCSTN p. Glu296Gly) is classified as benign based on allele frequency cut-offs. However, most missense variants reported in the literature demonstrated destabilizing effects with changes in conformational flexibility. These findings suggest that missense variants in HS-associated loci may contribute to disease by modulating protein activity in a variety of ways.

Discussion

This review provides a comprehensive summary of individual studies that investigate the genomic etiology of HS in its various forms; published variants to date are collated and appraised using the conservative ACMG-AMP criteria, genotype-phenotype associations assessed, and the structural impact of missense variants evaluated computationally. Our findings expound the locus and allelic heterogeneity underlying this inflammatory disorder and demonstrate a lack of robust correlation with clinical phenotypes. Herein we outline the physiological relevance of the HS-associated loci.

Despite the high heritability estimates of HS (77–80%) only a minority of HS patients demonstrate a strong monogenic etiology in the context of familial or syndromic HS (5%) (Kjaersgaard Andersen et al., 2021). Nevertheless, common forms of the disease demonstrate familial segregation. A family history of HS was documented in 41% in a cohort of 271 pediatric HS patients (Liy-Wong et al., 2021). The high heritability estimates reported by van Straalen et al suggest that sporadic forms of HS have a strong genetic element that contributes to their causality, despite the absence of fully penetrant variants causing multigenerational disease (Straalen et al., 2020). To date, the exact nature of the genetic variants driving common forms of HS remains unelucidated.

Based on Existing Knowledge on the Genomics of Hidradenitis Suppurativa, the Disease can Be Categorized as

  • 1. Sporadic HS: HS with no identified genetic variation to date

  • 2. Familial HS: HS with a strong family history and established underlying monogenic etiology

  • 3. Syndromic HS: HS in the setting of constellation of other clinical manifestation (PASH, PAPASH, SAPHO)

  • 4. HS+: HS in the setting of Dowling-Degos Disease (HS-DDD) or Familial Mediterranean Fever (HS-FMF).

Familial Hidradenitis Suppurativa: Variation in γ-Secretase Complex Protein-Coding Genes; Knocked down a Notch

Genetic variants in the GSC account for the majority of identified variants in fHS and sHS cases, but for only a minority of cases of sporadic HS. Cohort studies showed a low prevalence of GSC variants in sporadic forms of HS. The largest multicenter study in cases of predominantly Caucasian ethnicity identified pathogenic GSC variation in only 12 out of 188 (6.4%) patients with HS, of which 51% had fHS (). Smaller scale cohort studies in the United Kingdom revealed no GSC pathogenic variants in HS patients irrespective of family history of the disease (Ingram et al., 2013).

The human GSC is a multimeric, intramembrane-cleaving proteases composed of four subunit domains namely: Nicastrin (NCSTN), Presenilin Enhancer 2 (PEN2), Presenilin 1 (PSEN1) or PSEN2 and Anterior Pharynx Defective (APH) 1A or B. This gives rise to at least six different GSCs, which assemble fully in the endoplasmic reticulum and are transported to the cell membrane (). The GSCs are dynamic and can exist in three conformational states; extended, intermediate and compact (). Cryo-electron-microscopy single-particle analysis has elucidated the three-dimensional structure of human GCS, which was shown to have a horseshoe-shaped transmembrane domain (spanning 19 transmembrane segments) and a large extracellular domain (Lu et al., 2014).

The most widely reported variants in fHS lie in the nicastrin-coding gene NCSTN (OMIM #142690). Nicastrin is the largest subunit of the GSC (accounting for two-thirds of the molecular mass of the entire complex), and is postulated to be the substrate-recruiting protein of the GSC [specifically at the DYIGS and peptidase-like (DAP) region in the ectodomain (ECD)] (Shah et al., 2005). Nicastrin is essential for the assembly (particularly of the transmembrane domain) (Shah et al., 2005), maturation and stability of the GSC (). The protein has a bilobed ECD and a single transmembrane domain (TMD) at its C-terminus (Xie et al., 2014). The interface between the two lobes is maintained by extensive van der Waals contacts, amongst which those formed between Phe287 (of the large loop) nestled within a pocket of hydrophobic amino acids Phe103, Leu171, Phe176 and Ile180 (of the small loop), is highly conserved (Xie et al., 2014). A loop extending from the core of the small lobe of the nicastrin ECD forms a lid which covers the putative substrate binding site within the large lobe, amongst which the residue Trp164 is vital (Xie et al., 2014). This amino acid, as well as Pro-141, Trp-164, Asn-165 and Gly-168 have been shown to be highly conserved in the NCST “lid” domain, but not essential for regulating GSC activity, including Notch (Zhang X et al., 2016). Fluorescence imaging microscopy of intact cells detected conformational change of the nicastrin ECD, which is brought closer to the membrane core upon binding an inhibitor (). Residues Tyr337 and Glu333 (Shah et al., 2005) are both located within the substrate biding pocket ECD (Xie et al., 2014). The importance of Glu333 in proteolysis has been confirmed by mutagenesis studies, demonstrating abolished GSC cleavage, activity and maturation after substituting the residue (Shah et al., 2005; ), thus dispelling assertions that Glu333 is only involved in GSC maturation (). Nicastrin also forms complexes with PSEN1 and PSEN2, establishing a “secretasome” which allows for intramembranous proteolysis of the transmembrane proteins, including Notch (Yu et al., 2000).

The Notch signaling pathway is a highly conserved pathway involved in cell-cell communication. It regulates cellular differentiation and proliferation in continually renewing adult tissues such as skin. In these tissues, the notch receptor is activated by various ligands and cleaved by the GSC, releasing its intracellular domain which translocates to the nucleus to regulate gene expression (Mumm and Kopan, 2000). Because of the important roles played by Notch in epidermal and follicular homeostasis as well as inflammation, Notch dysregulation has been touted to underpin the molecular basis of HS in patients with pathogenic variants in GSC-protein coding genes (Okuyama et al., 2008; Melnik and Plewig, 2013). Interaction of the Notch receptor with its ligand (delta or jagged) results in two subsequent proteolytic cleavages of the receptor, the first of which is catalyzed by ADAM-family metalloproteinases and the second by the GSC. The product of the second cleavage, Notch intracellular domain (NICD), subsequently translocates to the nucleus where it acts as a transcriptional regulator for various genes () after complexing with CBF1-Suppressor of Hairless-LAG1 (CSL) and the co-activator mastermind (Wilson and Kovall, 2006).

In human models, downregulation of Notch signaling pathway has been shown to perturb keratinocyte differentiation and result in uncontrolled proliferation, disorganization of the suprabasal layers of the epidermis as well as dermal invasion (Thélu et al., 2002). These findings were also replicated in murine models wherein alteration in notch signaling resulted in altered sebaceous gland differentiation and terminal differentiation of the epidermis (Pan et al., 2004; ; Wang et al., 2008). Loss of ADAMS10 (responsible for notch receptor cleavage) () in murine models has been shown to result in impaired epidermal differentiation resulting in various pathologies including epidermal hyperproliferation and cyst formation as a result of altered notch signaling (Weber et al., 2011). Studies have also demonstrated that ADAMS10 is downregulated in HS (). Dysregulation of ADAM10-Notch signaling axis has been shown to impair the epithelial barrier and favor cutaneous dysbiosis (favoring Corynebacterium spp) (Sakamoto et al., 2021). Potentially, the altered microbiome promotes chronic inflammation by triggering the innate lymphoid cell population in an IL-17R dependent manner (Sakamoto et al., 2021). These findings may partly underpin the dysregulated cutaneous microbiome that accompanies HS (Mintoff et al., 2021a). Murine models have also demonstrated that disruption of notch nuclear target RBP-J results in cyst formation and epidermal hyperkeratinization (Yamamoto et al., 2003). A study scrutinizing publicly available genomic data revealed significant downregulation of Notch 1–4, and suggests ADAM17 as a key mediator in the pathogenesis of HS ().

Evidence for the role of Notch in HS can also be drawn from HS + disease such as HS-DDD. DDD is an autosomal dominant genodermatosis characterized by flexural and reticulated pigmentation. The condition is attributed to heterozygous variants in KRT5 (DDD1, OMIM #179850) at 12q13 and POFUT1 (DDD2, OMIM #615327) at 20q11. (; Stephan et al., 2021). Dubbed as “clinical collision” diseases, HS-DDD provides avenues for understanding pathophysiology and phenotypes (McGrath, 2018). Both POGLUT1 and POFUT1, causative genes in DDD, are established regulators of Notch pathway activity through their respective protein products namely protein-O glucosyltransferase 1 and protein O-fucosyltransferase 1 (Li et al., 2013; ). Congruently, patients with HS-DDD having underling POGLUT1 pathogenic variants demonstrate abnormal expression of genes encoding the critical element of the Notch pathway (Pavlovsky et al., 2018). Further molecular evidence is derived from two patients with HS-DDD, where reduced expression of NOTCH1 and NCSTN mRNA was demonstrated in lesional skin when compared to non-lesional skin, (Penha et al., 2020). HS-DDD with underlying POFUT1 pathogenic variants has been suggested to share similar Notch disturbance; however robust serological and in-vitro studies are lacking (). Indirect evidence supporting the role of Notch downregulation in HS is provided by a case report in which a patient treated with a notch signaling inhibitor AL101 (BMS-906024) developed HS (Wiggins and Chon, 2020).

Conflicting findings have also been reported. Nicastrin, Notch 1–3, PIK3R3 and AKT3 levels were found to be significantly higher in lesional skin of 60 HS patients when compared to healthy controls. In lesional skin, these proteins were significantly higher in patients with mild (Hurley stage 1) disease compared to those with moderate and severe disease (Hurley stage II and III), despite excluding smoking and obesity as confounding factors (Hessam et al., 2021). Nicastrin overexpression (particularly dermal) has been associated with hypertrophic scarring as well as with inhibition of Notch signaling resulting in the suppressed production of fibrotic factors such as collagen 1 and 3 and TGF-β1 (). Functional studies have shown that various HS-inducing nicastrin missense variants are active and sustain Notch signaling, and therefore do not fully support the concept of notch as being the singular pathophysiological processes involved in NCSTN-associated HS (Zhang and Sisodia, 2015). Indirect evidence for upregulation of notch can be drawn from other inflammatory pathologies. In patients with psoriasis, the proinflammatory cytokine serum amyloid A (SAA), known to be highly elevated in sera of HS patients (Witte-Händel et al., 2019), has been shown to upregulate Notch1 activity (Rooney et al., 2014).

PSEN has also been implicated in Notch signaling. The homologs PSEN1/PSEN2 are the catalytic subunit of the GSC. PSEN1/GSC is widely distributed in the cell (including its plasma membrane) whilst PSEN2/GSC is mostly restricted to late endosomes and lysosomes (Sannerud et al., 2016). Auto-compensatory mechanisms maintain PSEN levels in equilibrium (Stanga et al., 2018). In animal models, only zebrafish affected by the familial acne inversa-like indel mutation psen1. ptrp233fs (equivalent to human PSEN1 codon P242) had shown a significant alteration in Notch signaling (as opposed to early onset familial Alzheimer disease mutants). Upregulation of genes involved in inflammation was also observed in these mutants (). The apparent upregulation of Notch signaling may possibly be accounted for by transcriptional adaptation, the process by which fragments of mutated mRNA translocate to the nucleus leading to transcriptional modulation of “adapting genes” (Sztal and Stainier, 2020). HS patients with underlying PSEN variants are designated OMIM # 613737.

Variants of Presenilin enhancer 2 (PSENEN), which codes for presenilin enhancer 2 (PEN2) have also been described in both sporadic HS as well as HS + DDD. The role of PEN2 in GSC function and Notch signaling was found to be conserved across species (). PEN2 is the last unit to be incorporated within the GSC, with a PEN2 “retention mechanism” ensuring that only fully assembled GSCs are released from the endoplasmic reticulum to the plasma membrane (; ). The incomplete penetrance of PSENEN pathogenic variants has been described in three families by Riis et al (Theut Riis et al., 2020). Potentially, this can be attributed to the fact that PEN2 is not part of the GSC proteolytic domain. Additionally, it is possible that monoallelic pathogenic variants may not cause disease in the absence of other risk factors. In silico studies further support the concept that heterozygous pathogenic variants in NCSTN and PSENEN are not sufficient to cause disease (Nomura et al., 2014; Theut Riis et al., 2020).

APH-1 is the least well-characterized locus in the setting of HS, with a single APH-1B variant (p.His170Arg) having been associated with HS (Theut Riis et al., 2020). The authors postulate that this variant is unlikely to be causative of HS, citing studies which demonstrate much higher APH-1A expression in skin and fibroblast models in which APH-1A exclusively is involved in Notch signaling (Theut Riis et al., 2020). APH1 is a 7-transmembrane helix protein expressed as two homologous isoforms in humans, encoded by two genes (APH1a on chromosome 1; APH1b on chromosome 15). Both APH-1A and APH-1B adopt a water channel topology and transport water across the plasma membrane (). The conserved His170 residue together with His196 play a major role in water transportation across the lipid bilayer (; ).

The significance of GSC variants and the disruption in Notch signaling pathways and its targets in HS, is still evolving. Further functional and multiomic studies are required to determine the definitive role of the Notch signaling pathway in skin disease, including HS (). A working model of HS pathophysiology suggests that underlying genetic variants lead to lower protein expression which becomes functionally relevant under cellular stress mediated by friction (obesity), temperature and dysbiosis (Pink et al., 2016).

Syndromic Hidradenitis Suppurativa

In a subset of patients, HS develops as part of a constellation of other inflammatory, conditions (sHS). The classical HS syndromes in which genetic variation has been described include PASH (pyoderma gangrenosum, acne and suppurative hidradenitis), PAPASH (pyogenic arthritis + PASH) and SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndromes (). A PSTPIP1 pathogenic variant was recently identified in a patient with proctitis, pyoderma gangrenosum, HS and fever (dubbed “PPHSF” syndrome) (Hieta et al., 2021). Supplementary Table S2 summarizes the genetic variants associated with sHS.

Braun-Falco et al., had documented the first two families with PASH. No pathogenic variants in PSTPIP1 were detected; however afflicted patients had hemi-allelic increase of the CCTG microsatellite motif (). Other cases of PASH without PSTPIP1 pathogenic variants have also been reported (; Niv et al., 2017; Lamiaux et al., 2018). Similarly, no pathogenic variants were described in other forms of sHS namely, PsAPASH (Psoriatic arthritis and PASH) syndrome (Saraceno et al., 2015), PsAPSASH (Psoriasis, arthritis, pyoderma gangrenosum, synovitis, acne, suppurative hidradenitis) (Nikolakis et al., 2021) and PASS (pyoderma gangrenosum, acne, hidradenitis suppurativa and ankylosing spondylitis) (; Leuenberger et al., 2016) syndromes. Follicular occlusion syndromes such as the follicular occlusion triad [HS, acne conglobata and dissecting cellulitis of the scalp (Perifolliculitis capitis abscedens et suffodiens)] () and the follicular tetrad (Vasanth and Chandrashekar, 2014) (follicular triad and pilonidal sinus) are described but likewise, they also lack an identified genetic driver.

PSTPIP1 is the locus most frequently implicated in sHS that features in PASH, PAPASH and PPHSF syndromes. Interestingly, PSTPIP1 variants have not been described in isolated forms of HS. PSTPIP1 codes for Proline-serine-threonine phosphatase-interacting protein 1. It has been demonstrated that PSTPIP1 regulates the transition of macrophage’s podosomes to filopodia-like protrusions and modulates their invasive migration (Starnes et al., 2014). Cellular studies have also demonstrated that pyrin modulates the intracellular distribution of PSTPIP1, and co-localizes at the leading edge of cells mitigating cell migration (Shoham et al., 2003; Waite et al., 2009; ). In fact, PTSPIP1 mutant T-cells were shown to have altered f-actin polymerization (Janssen et al., 2018).

MEFV variants have been shown to be more frequent in patients with HS than healthy controls (Vural et al., 2019). A patient of Turkish origin suffering from comorbid PASH and familial Mediterranean fever (FMF) has been described. Targeted analysis in the MEFV gene identified the two heterozygous pathogenic variants (p.M680I and p. V726A); assessment of the rest of his genome was therefore lacking (Vural et al., 2017). Interestingly, a patient with PAPASH was heterozygous for a microsatellite elongation in the PSTPIP1 promotor region, and homozygous for the pathogenic MEFV p. Met694Val variant. However, he was asymptomatic for FMF. The authors suggest that this could possibly be the result of aberrant mutant Pyrin-PTSPIP1 interaction (Vural et al., 2019). The cause-effect relationship underlying the coexistence of a systemic proinflammatory susceptibility typical of FMF with inflammation of the PSU remains to be established.

Cytokine IL-1β may be the common denominator linking variants described in sHS or HS in combination with pyoderma gangrenosum (; Witte-Händel et al., 2019). The protein products encoded by PSTPIP1 and MEFV interact in a multimeric protein complex that regulates assembly and activation of the inflammasome by promoting ASC oligomerization and Caspase-1 activation (Yu et al., 2007). The inflammasome regulates innate immunity and epithelial barrier defenses. On the other hand, gain of function mutations in NLRP3 result in increased IL-1 [a defining feature of Cryopyrin-associated periodic syndrome (CAPS)] (Kuemmerle-Deschner et al., 2017). Conflicting results have been observed with regards to IL-1β levels in patients with sHS. No statistically significant differences in serum Il-1β levels were described between patients with PASH syndrome and healthy controls (Marzano et al., 2014). Conversely, PASS has been characterized as an IL-1-driven autoinflammatory disease which responds to treatment with the Il-1 Receptor antagonist anakinra (Leuenberger et al., 2016). Anakinra has been proven to be ineffective in the treatment of a young female with PASH syndrome (Staub et al., 2015).

HS has also been documented to manifest in the setting of specific chromosomal disorders, where it does not constitute a classical diagnostic feature. It has been speculated that diminished Notch receptor processing and signaling could account for HS is the setting of Trisomy 21; however a definitive functional correlation remains elusive (). A case report also describes the occurrence of unilaterally distributed HS, possibly due to constitutional mosaicism in a patient with trisomy 1q (Skroza et al., 2019).

Hidradenitis Suppurativa +

HS has been independently described in the setting of two other heritable conditions namely, HS-DDD and Familial Mediterranean Fever (HS-FMF).

A distinctive subtype of Dowling-Degos with HS (HS-DDD) is defined by heterozygous variants in PSENEN (OMIM # 613736) on 19q13. Patients having underlying PSENEN variants but suffering from DDD exclusively have been described (Ralser et al., 2017; Ren and Zeng, 2020). Interestingly, only obese family members harboring the pathogenic PSENEN c.62-1G > C splice variant manifested HS + DDD, whilst their lean, non-smoking relative who also harbored the same mutation manifested DDD exclusively (Ralser et al., 2017). Non-smoking, lean patients from another family having PSENEN 84_85insT variant manifested DDD without HS (Ralser et al., 2017). On the other hand, the c.216delC PSENEN variant was described in non-smoking, lean patients from two separate families manifesting DDD exclusively but also in an unrelated patient with DDD-HS, whose smoking history and weight were not documented (Ralser et al., 2017; Ren and Zeng, 2020; Theut Riis et al., 2020). This suggests that in the context of HS, PSENEN pathogenic variants exhibit incomplete penetrance and variable expressivity, and possibly only manifest disease in the setting of specific triggers such as obesity. A pathogenic NCSTN nonsense variant p. Arg583Ter (c.1747C > T) has also been described in a lean, non-smoking patient with HS-DDD. The variant segregated with the DDD phenotype, but not HS, in the proband’s daughter (; ). However, the pathogenicity of this variant and its relevance to HS-DDD has been disputed, mainly because the significance of co-existing KRT5 variants was downplayed and deemed benign ().

HS can occur in combination with other inherited autoinflammatory syndromes. Two patients with co-morbid HS - mevalonate kinase deficiency (), an autosomal recessive inborn error of metabolism which leads to chronic inflammation, have been described. Various studies have also described the co-existance of an HS phenotype in patients bearing pathogenic variation at the MEFV locus (; Vural et al., 2017; Jfri et al., 2019; Vural et al., 2019). This gene encodes pyrin, a protein which modulates the activity of the GSC. These studies suggest that HS and FMF are autoinflammatory disorders that may possibly share converging pathophysiologic processes. Despite the systemic proinflammatory state in these conditions, proof of causal associations remains lacking.

Genotype-Phenotype Correlations

Patients with HS exhibit extensive phenotypic heterogeneity making genotype-phenotype correlations difficult to establish (Kent, 2009). The task is further complicated by poor interrater reliability of HS phenotypes (van Straalen et al., 2018), differences in severity scoring (Zouboulis et al., 2019) as well as evidence of pleiotropism (). Notwithstanding, some general patterns are emerging, and encouraging results are emerging even from relatively low-powered studies (Marzano et al., 2022). HS patients having underlying NCSTN variants appear to have a follicular-type HS, in which comedones, papules and folliculitis predominate. Patients with this subtype of HS are likelier to manifest lesions in the nape and back and have co-morbid pilonidal sinus disease (PND) (Xu et al., 2016), a common co-morbidity and a possible intergluteal localization of disease in HS patients (). Similarly, phenotyping of a large cohort of HS patients showed that cases exhibiting a follicular (LC2) type phenotype, typified by epidermal cysts, PND and comedones were more likely to have a family history of HS when compared to the patients with axillary-mammary (LC1) and gluteal (LC3) phenotypes (). An inverse correlation between LC1 HS phenotypes and NCSTN variants has been described (). Patients with an endotype defined by GSC pathogenic variants and higher levels of serum IL-10 are more likely to be non-obese males with predominantly nodular lesions on the trunk and posterior sites and have a history of PND (referred to as “Cluster 1” HS patients). On the other hand, patients with high serum IL-1, IL-17, IL-16 and CRP are more likely to be obese and have later-onset disease, with tunnels and abscesses predominating (Cluster 2) (). With regards to patients with sHS, both promoter and PSTPIP1 variants were found to be significantly associated with syndromic forms of disease ().

In a broader sense, HS patients having an affected first-degree relative develop more severe disease at a younger age than their parents. The gender of the affected parents also influences the resulting phenotype in the offspring, with patients having an affected mother more frequently reporting axillary involvement, and patients with affected fathers being significantly more likely to involve the buttocks and the genitals. The mean number of affected body sites was found to be significantly higher in patients whose father has HS then those with a maternal history of the condition (Plenary Lectures, 2019).

Patients who are obese and smokers and without any underlying genetic variants are more likely to present with a “wet” phenotype characterized by draining abscesses in intertriginous regions. Conversely, lean non-smokers with a known family history are more likely to develop a “dry” phenotype characterized by follicular lesions in atypical regions such as the nuchal area and antecubital fossae (Vossen et al., 2020a; Mintoff et al., 2021b), or with syndromic HS.

Hidradenitis Suppurativa Genomics—Caveats and Challenges

The interpretation of genetic findings in HS presents several limitations. When compared to other common complex traits, there is a deficiency of large-scale genomic studies on ethnically diverse cohorts. The relative contribution of common vs. rare polymorphisms remains unascertained. Applying high-throughput sequencing studies to kindreds with early-onset familial or atypical HS phenotypes is a valid approach. However, variant prioritization and pathogenicity scoring can be complicated by pitfalls such as the overreliance on in-silico predictors and the use of inappropriate allele frequency cut-offs. Additionally, limited conclusions about the role of monoallelic variants causing recessive disorders can be drawn. It must be acknowledged that the assessment of allele frequencies in aggregate datasets unselected for disease, such as GnomAD, is a valuable approach. However, the presence of rare variants causative of late-onset disease in genomic databases can confound variant classification (Lek et al., 2016). Attributing causality to variants remains a considerable challenge, particularly for missense substitutions that are not structurally deleterious. Functional evaluation using in-vitro or in-vivo models are required to support pathogenicity and robustly define gene-disease associations for disputed loci. This is reinforced by conflicting interpretations of pathogenicity attributed to some variants in clinical databases. Furthermore, studies based on exome capture and sequencing may fail to identify deep intronic variants that modulate splicing or pathogenic structural variation. In the broader context of HS genomic architecture, it is essential to consider that studies sequencing cases with multigenerational early-onset disease are likely to skew towards the identification of high-penetrance variants. These represent the ‘low-hanging fruit’ of genomic discovery, at the expense of variants that lack adequate penetrance to drive familial segregation of disease. Plausibly, such intermediate penetrance variants predispose to later onset or milder disease.

This review is intrinsically limited by study selection criteria, and it is possible that some studies may not have been included (language other than English, Italian and Spanish, articles missing key data and conference proceedings). In addition, key phenotypic data, such as obesity and smoking status, as well as familial segregation of identified variants was not reported by some investigators.

Conclusion

The extent to which HS pathogenesis and risk are driven by the shared overlap between comorbid clinical risk factors, such as obesity and smoking, and one’s genetic predisposition remains unknown. The degree to which different variants contribute to the two main pathophysiological processes at the PSU namely hyperkeratosis and inflammation (Nomura, 2020) also remains unelucidated. The weak genotype-phenotype associations observed in HS are similar to other complex diseases. Potentially, this can be attributed to diagnostic delays, phenotypic heterogeneity and pleiotropic genetic effects acting against background modifiers such as changes in the composition of the skin microbiome.

Notwithstanding, the limited number of studies investigating HS by whole exome sequencing, and to a lesser extent by whole genome sequencing, show promising results and highlight the need for patients at the extreme ends of the HS phenotypic spectrum to be identified and prioritized for rare variant screening. To this end, phenotypic evaluation and categorization criteria need to be standardized to facilitate their use and interpretation in clinical care settings (; ).

The incompletely understood genomic risk factors of HS warrants further study, possibly by alternative approaches such as genome-wide association studies (GWAS). GWAS should elucidate the contribution of common genomic variants to HS and potentially identify new loci associated with this trait. Such endeavors require large-scale multicenter, collaborative genomic efforts (; Jabbour et al., 2021) which will allow for endotyping (), deep phenotyping and, ultimately precision medicine (Robinson, 2012; ) for HS patients. Genetic variables also have the propensity to act as diagnostic and predictive HS biomarkers (). The evidence outlined in this review suggests that considering HS as a single disease may be misleading. Conversely, considering a precision-medicine approach tailored to every individual may be unrealistic in health care systems burdened by limited access to genetic testing and escalating health care costs. Important lessons can be derived from studies of other complex traits. Several investigators have shown that precision phenotyping of polygenic disease based on disease mechanisms is superior to traditional clinical classifications as it better identifies patients at risk of complications and can guide therapeutic choices (). Whether or not dissecting the phenotypic heterogeneity of HS improves clinical outcomes remains to be assessed.

Statements

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2022.861241/full#supplementary-material

References

  • 1

    AbbaraS.Georgin-LavialleS.Stankovic StojanovicK.BachmeyerC.SenetP.BuobD.et al (2017). Association of Hidradenitis Suppurativa and Familial Mediterranean Fever: A Case Series of 6 Patients. Jt. Bone Spine.84 (2), 159162. 10.1016/j.jbspin.2016.02.021

  • 2

    Aguayo-OrtizR.DominguezL. (2019). APH-1A Component of γ-Secretase Forms an Internal Water and Ion-Containing Cavity. ACS Chem. Neurosci.10 (6), 29312938. 10.1021/acschemneuro.9b00150

  • 3

    AhlqvistE.StormP.KäräjämäkiA.MartinellM.DorkhanM.CarlssonA.et al (2018). Novel Subgroups of Adult-Onset Diabetes and Their Association with Outcomes: a Data-Driven Cluster Analysis of Six Variables. Lancet Diabetes Endocrinol.6 (5), 361369. 10.1016/s2213-8587(18)30051-2

  • 4

    Akkaya-UlumY. Z.Balci-PeynirciogluB.PuraliN.YilmazE. (2015). Pyrin-PSTPIP1 Colocalises at the Leading Edge during Cell Migration. Cell Biol Int.39 (12), 13841394. 10.1002/cbin.10514

  • 5

    BarthelsonK.DongY.NewmanM.LardelliM. (2021). PRESENILIN 1 Mutations Causing Early-Onset Familial Alzheimer's Disease or Familial Acne Inversa Differ in Their Effects on Genes Facilitating Energy Metabolism and Signal Transduction. J. Alzheimers Dis.82 (1), 327347. 10.3233/JAD-210128

  • 6

    BasmanavF. B.OprisoreanuA.-M.PasternackS. M.ThieleH.FritzG.WenzelJ.et al (2014). Mutations in POGLUT1, Encoding Protein O-Glucosyltransferase 1, Cause Autosomal-Dominant Dowling-Degos Disease. Am. J. Hum. Genet.94 (1), 135143. 10.1016/j.ajhg.2013.12.003

  • 7

    BenhadouF.Vlaeminck-GuillemV.DuquesneA.MintoffD.GuillemP. (2021). Association hidradénite suppurée et déficit en mévalonate kinase : deux cas. Ann. Dermatol. Vénéréologie - FMC.1 (8Suppl. 1), 1A2767. 10.1016/j.fander.2021.09.282

  • 8

    BenhadouF.Van der ZeeH. H.PascualJ. C.RigopoulosD.KatoulisA.LiakouA. I.et al (2019). Pilonidal Sinus Disease: an Intergluteal Localization of Hidradenitis Suppurativa/acne Inversa: a Cross‐sectional Study Among 2465 Patients. Br. J. Dermatol.181 (6), 11981206. 10.1111/bjd.17927

  • 9

    BlanpainC.LowryW. E.PasolliH. A.FuchsE. (2006). Canonical Notch Signaling Functions as a Commitment Switch in the Epidermal Lineage. Genes Dev.20 (21), 30223035. 10.1101/gad.1477606

  • 10

    BorggrefeT.OswaldF. (2009). The Notch Signaling Pathway: Transcriptional Regulation at Notch Target Genes. Cell. Mol. Life Sci.66 (10), 16311646. 10.1007/s00018-009-8668-7

  • 11

    BrandãoL. A. C.TricaricoP. M.GrattonR.AgrelliA.ZupinL.Abou-SalehH.et al (2021). Multiomics Integration in Skin Diseases with Alterations in Notch Signaling Pathway: PlatOMICs Phase 1 Deployment. Int. J. Mol. Sci.22 (4), 1523. 10.3390/ijms22041523

  • 12

    Braun-FalcoM.KovnerystyyO.LohseP.RuzickaT. (2012). Pyoderma Gangrenosum, Acne, and Suppurative Hidradenitis (PASH)?a New Autoinflammatory Syndrome Distinct from PAPA Syndrome. J. Am. Acad. Dermatol.66 (3), 409415. 10.1016/j.jaad.2010.12.025

  • 13

    BruzzeseV. (2012). Pyoderma Gangrenosum, Acne Conglobata, Suppurative Hidradenitis, and Axial Spondyloarthritis. J. Clin. Rheumatol.18 (8), 413415. 10.1097/rhu.0b013e318278b84c

  • 14

    Calderón-CastratX.Bancalari-DíazD.Román-CurtoC.Romo-MelgarA.Amorós-CerdánD.Alcaraz-MasL. A.et al (2016). PSTPIP1 Gene Mutation in a Pyoderma Gangrenosum, Acne and Suppurative Hidradenitis (PASH) Syndrome. Br. J. Dermatol.175 (1), 194198. 10.1111/bjd.14383

  • 15

    Canoui-PoitrineF.Le ThuautA.RevuzJ. E.VialletteC.GabisonG.PoliF.et al (2013). Identification of Three Hidradenitis Suppurativa Phenotypes: Latent Class Analysis of a Cross-Sectional Study. J. Invest. Dermatol.133 (6), 15061511. 10.1038/jid.2012.472

  • 16

    CapellA.BeherD.ProkopS.SteinerH.KaetherC.ShearmanM. S.et al (2005). γ-Secretase Complex Assembly within the Early Secretory Pathway. J. Biol. Chem.280 (8), 64716478. 10.1074/jbc.m409106200

  • 17

    Chávez-GutiérrezL.ToliaA.MaesE.LiT.WongP. C.de StrooperB. (2008). Glu(332) in the Nicastrin Ectodomain Is Essential for Gamma-Secretase Complex Maturation but Not for its Activity. J. Biol. Chem.283 (29), 2009620105. 10.1074/jbc.M803040200

  • 18

    ChenL.ZhangX.YuZ.SongY.WangT.YangK.et al (2021). Inhibition of Notch Intracellular Domain Suppresses Cell Activation and Fibrotic Factors Production in Hypertrophic Scar Fibroblasts versus Normal Skin Fibroblasts. Ann. Plast. Surg.86 (4), 400405. 10.1097/sap.0000000000002540

  • 19

    ChicarilliZ. N. (1987). Follicular Occlusion Triad: Hidradenitis Suppurativa, Acne Conglobata, and Dissecting Cellulitis of the Scalp. Ann. Plast. Surg.18 (3), 230237. 10.1097/00000637-198703000-00009

  • 20

    ChristophK.JohannaS.MatthiasF. (2007). Endoplasmic Reticulum Retention of the γ-secretase Complex Component Pen2 by Rer1. EMBO Rep.8, 743748. 10.1038/sj.embor.7401027

  • 21

    CrovatoF.NazzariG.ReboraA. (1983). Dowling-Degos Disease (Reticulate Pigmented Anomaly of the Flexures) Is an Autosomal Dominant Condition. Br. J. Dermatol.108 (4), 473476. 10.1111/j.1365-2133.1983.tb04602.x

  • 22

    DanbyF. W.JemecG. B. E.MarschW. C.von LaffertM. (2013). Preliminary Findings Suggest Hidradenitis Suppurativa May Be Due to Defective Follicular Support. Br. J. Dermatol.168 (5), 10341039. 10.1111/bjd.12233

  • 23

    DaxheletM.DaoudM.SuppaM.BenhadouF.NjimiH.TzellosT.et al (2021). European Registry for Hidradenitis Suppurativa: State of Play. J. Eur. Acad. Dermatol. Venereol.35 (4), e2746. 10.1111/jdv.17023

  • 24

    DaxheletM.SuppaM.WhiteJ.BenhadouF.ThorlaciusL. R.JemecG. B. E.et al (2020). Proposed Definitions of Typical Lesions in Hidradenitis Suppurativa. Dermatology.236 (5), 431438. 10.1159/000507348

  • 25

    DehuryB.KeppK. P. (2021). Membrane Dynamics of γ‐secretase with the Anterior Pharynx‐defective 1B Subunit. J. Cell Biochem122 (1), 6985. 10.1002/jcb.29832

  • 26

    DeludeC. M. (2015). Deep Phenotyping: The Details of Disease. Nature527 (7576), S14S15. 10.1038/527s14a

  • 27

    Der SarkissianS.HessamS.KirbyJ. S.LowesM. A.MintoffD.NaikH. B.et al (2022). Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa. JAMA Dermatol.10.1001/jamadermatol.2021.4926

  • 28

    DriesD. R.ShahS.HanY.-H.YuC.YuS.ShearmanM. S.et al (2009). Glu-333 of Nicastrin Directly Participates in γ-Secretase Activity. J. Biol. Chem.284 (43), 2971429724. 10.1074/jbc.m109.038737

  • 29

    DuchateletS.MiskinyteS.DelageM.UngeheuerM.-N.LamT.BenhadouF.et al (2020). Low Prevalence of GSC Gene Mutations in a Large Cohort of Predominantly Caucasian Patients with Hidradenitis Suppurativa. J. Invest. Dermatol.140 (10), 20852088. 10.1016/j.jid.2019.10.025

  • 30

    DuchateletS.MiskinyteS.Join‐LambertO.UngeheuerM. N.FrancèsC.NassifA.et al (2015). First Nicastrin Mutation in PASH (Pyoderma Gangrenosum, Acne and Suppurative Hidradenitis) Syndrome. Br. J. Dermatol.173 (2), 610612. 10.1111/bjd.13668

  • 31

    EladN.De StrooperB.LismontS.HagenW.VeugelenS.ArimonM.et al (2015). The Dynamic Conformational Landscape of Gamma-Secretase. J. Cell Sci.128 (3), 589598. 10.1242/jcs.164384

  • 32

    Faraji ZonoozM.Sabbagh-KermaniF.FattahiZ.FadaeeM.AkbariM. R.AmiriR.et al (2016). Whole Genome Linkage Analysis Followed by Whole Exome Sequencing Identifies Nicastrin (NCSTN) as a Causative Gene in a Multiplex Family with γ-Secretase Spectrum of Autoinflammatory Skin Phenotypes. J. Invest. Dermatol.136 (6), 12831286. 10.1016/j.jid.2016.02.801

  • 33

    FitzsimmonsJ. S.FitzsimmonsE. M.GilbertG. (1984). Familial Hidradenitis Suppurativa: Evidence in Favour of Single Gene Transmission. J. Med. Genet.21 (4), 281285. 10.1136/jmg.21.4.281

  • 34

    FitzsimmonsJ. S.GuilbertP. R. (1985). A Family Study of Hidradenitis Suppurativa. J. Med. Genet.22 (5), 367373. 10.1136/jmg.22.5.367

  • 35

    FitzsimmonsJ. S.GuilbertP. R.FitzsimmonsE. M. (1985). Evidence of Genetic Factors in Hidradenitis Suppurativa. Br. J. Dermatol.113 (1), 18. 10.1111/j.1365-2133.1985.tb02037.x

  • 36

    FrancisR.McGrathG.ZhangJ.RuddyD. A.SymM.ApfeldJ.et al (2002). aph-1 and Pen-2 Are Required for Notch Pathway Signaling, γ-Secretase Cleavage of βAPP, and Presenilin Protein Accumulation. Developmental Cell3 (1), 8597. 10.1016/s1534-5807(02)00189-2

  • 37

    FrewJ. W.HawkesJ. E.Sullivan‐WhalenM.GilleaudeauP.KruegerJ. G. (2019). Inter‐rater Reliability of Phenotypes and Exploratory Genotype-Phenotype Analysis in Inherited Hidradenitis Suppurativa. Br. J. Dermatol.181 (3), 566571. 10.1111/bjd.17695

  • 38

    FrewJ. W.LowesM. A.GoldfarbN.ButtM.PiguetV.O’BrienE.et al (2021). Global Harmonization of Morphological Definitions in Hidradenitis Suppurativa for a Proposed Glossary. JAMA Dermatol.157 (4), 449455. 10.1001/jamadermatol.2020.5467

  • 39

    FrewJ. W.NavrazhinaK. (2020). No Evidence that Impaired Notch Signalling Differentiates Hidradenitis Suppurativa from Other Inflammatory Skin Diseases. Br. J. Dermatol.182 (4), 10421043. 10.1111/bjd.18593

  • 40

    GalimbertiR. L.VacasA. S.Bollea GarlattiM. L.TorreA. C. (2016). The Role of Interleukin-1β in Pyoderma Gangrenosum. JAAD Case Rep.2 (5), 366368. 10.1016/j.jdcr.2016.07.007

  • 41

    GaoM.WangP.-G.CuiY.YangS.ZhangY.-H.LinD.et al (2006). Inversa Acne (Hidradenitis Suppurativa): a Case Report and Identification of the Locus at Chromosome 1p21.1-1q25.3. J. Invest. Dermatol.126 (6), 13021306. 10.1038/sj.jid.5700272

  • 42

    GarcovichS.GenoveseG.MoltrasioC.MalvasoD.MarzanoA. V.PapashPs. A. P. A. S. H. (2021). PASH, PAPASH, PsAPASH, and PASS: The Autoinflammatory Syndromes of Hidradenitis Suppurativa. Clin. Dermatol.39 (2), 240247. 10.1016/j.clindermatol.2020.10.016

  • 43

    GarcovichS.TricaricoP. M.MeddourC. N.GiovanardiG.PerisK.CrovellaS.et al (2021). Comorbid Acne Inversa and Dowling-Degos Disease Due to a Single NCSTN Mutation: Is There Enough Evidence? Reply from the Authors. Br. J. Dermatol.184 (2), 375376. 10.1111/bjd.19543

  • 44

    GarcovichS.TricaricoP. M.Nait‐MeddourC.GiovanardiG.PerisK.CrovellaS.et al (2020). Novel Nicastrin Mutation in Hidradenitis Suppurativa-Dowling-Degos Disease Clinical Phenotype: More Than Just Clinical Overlap?Br. J. Dermatol.183 (4), 758759. 10.1111/bjd.19121

  • 45

    GasparicJ.Theut RiisP.JemecG. B. (2017). Recognizing Syndromic Hidradenitis Suppurativa: a Review of the Literature. J. Eur. Acad. Dermatol. Venereol.31 (11), 18091816. 10.1111/jdv.14464

  • 46

    González-MansoA.Agut-BusquetE.RomaníJ.VilarrasaE.BittencourtF.MensaA.et al (2020). Hidradenitis Suppurativa: Proposal of Classification in Two Endotypes with Two-step Cluster Analysis. Dermatology.237 (3), 365377. 10.1159/000511045

  • 47

    González-VillanuevaI.GutiérrezM.HispánP.BetllochI.PascualJ. C. (2018). Novel POFUT1 Mutation Associated with Hidradenitis Suppurativa-Dowling-Degos Disease Firm up a Role for Notch Signalling in the Pathogenesis of This Disorder. Br. J. Dermatol.178 (4), 984986. 10.1111/bjd.16264

  • 48

    Gracia-CazañaT.FriasM.RosellóR.Vera-ÁlvarezJ.GilaberteY. (2015). PASH Syndrome Associated with Osteopoikilosis. Int. J. Dermatol.54 (9), e369371. 10.1111/ijd.12827

  • 49

    GrattonR.TricaricoP. M.MoltrasioC.Lima Estevão de OliveiraA. S.BrandãoL.MarzanoA. V.et al (2020). Pleiotropic Role of Notch Signaling in Human Skin Diseases. Int. J. Mol. Sci.21 (12), E4214. 10.3390/ijms21124214

  • 50

    GrootA. J.VooijsM. A. (2012). The Role of Adams in Notch Signaling. Adv. Exp. Med. Biol.727, 1536. 10.1007/978-1-4614-0899-4_2

  • 51

    HeY.XuH.LiC.ZhangX.ZhouP.XiaoX.et al (2019). Nicastrin/miR-30a-3p/RAB31 Axis Regulates Keratinocyte Differentiation by Impairing EGFR Signaling in Familial Acne Inversa. J. Invest. Dermatol.139 (1), 124134. 10.1016/j.jid.2018.07.020

  • 52

    HermaschM. A.SchönM. P.FrankJ. (2020). Comorbid Acne Inversa and Dowling-Degos Disease Due to a Single NCSTN Mutation - Is There Enough Evidence?Br. J. Dermatol.184 (2), 374. 10.1111/bjd.19539

  • 53

    HessamS.GambichlerT.SkryganM.SchollL.SandM.MeyerT.et al (2021). Increased Expression Profile of NCSTN, Notch and PI3K/AKT3 in Hidradenitis Suppurativa. J. Eur. Acad. Dermatol. Venereol.35, 203. 10.1111/jdv.16962

  • 54

    HietaN.NuutinenH.RoivasJ.SalminenK.KujariH.TalveL.et al (2021). Severe Ulcerative Proctitis, Pyoderma Gangrenosum, Hidradenitis Suppurativa and Fever in a Patient with a Rare Variant of the PSTPIP1 Gene. Clin. Exp. Dermatol.46 (7), 13871390. 10.1111/ced.14754

  • 55

    IngramJ. R.WoodM.JohnB.ButlerR.AnsteyA. V. (2013). Absence of Pathogenic γ-secretase Mutations in a South Wales Cohort of Familial and Sporadic Hidradenitis Suppurativa (Acne Inversa). Br. J. Dermatol.168 (4), 874876. 10.1111/bjd.12048

  • 56

    IttisoponpisanS.IslamS. A.KhannaT.AlhuzimiE.DavidA.SternbergM. J. E. (2019). Can Predicted Protein 3D Structures Provide Reliable Insights into whether Missense Variants Are Disease Associated?J. Mol. Biol.431 (11), 21972212. 10.1016/j.jmb.2019.04.009

  • 57

    JabbourA. J.van StraalenK. R.ColvinA.PrensE. P.PetukhovaL. (2021). Clinical Translation of Hidradenitis Suppurativa Genetic Studies Requires Global Collaboration. Br. J. Dermatol.186 (1), 183185. 10.1111/bjd.20749

  • 58

    JanssenW. J. M.GrobarovaV.LeleuxJ.JongeneelL.van GijnM.van MontfransJ. M.et al (2018). Proline-serine-threonine Phosphatase Interacting Protein 1 (PSTPIP1) Controls Immune Synapse Stability in Human T Cells. J. Allergy Clin. Immunol.142 (6), 19471955. 10.1016/j.jaci.2018.01.030

  • 59

    JfriA.LitvinovI. V.NetchiporoukE.O'BrienE. (2020). Novel Variants of MEFV and NOD2 Genes in Familial Hidradenitis Suppurativa: A Case Report. SAGE Open Med. Case Rep.8, 2050313X20953113. 10.1177/2050313X20953113

  • 60

    JfriA. H.O’BrienE. A.LitvinovI. V.AlaviA.NetchiporoukE. (2019). Hidradenitis Suppurativa: Comprehensive Review of Predisposing Genetic Mutations and Changes. J. Cutan. Med. Surg.23 (5), 519527. 10.1177/1203475419852049

  • 61

    JfriA.NassimD.O’BrienE.GulliverW.NikolakisG.ZouboulisC. C. (2021). Prevalence of Hidradenitis Suppurativa. JAMA Dermatol.157 (8), 924931. 10.1001/jamadermatol.2021.1677

  • 62

    JiaoT.DongH.JinL.WangS.WangJ. (2013). A Novel Nicastrin Mutation in a Large Chinese Family with Hidradenitis Suppurativa. Br. J. Dermatol.168 (5), 11411143. 10.1111/bjd.12135

  • 63

    KanT.TakahagiS.ShindoH.TanakaA.KawaiM.HideM. (2018). A Unique Clinical Phenotype of a Patient Bearing a Newly Identified Deletion Mutation in the PSENEN Gene along with the Pathogenic Serum Desmoglein-1 Antibody. Clin. Exp. Dermatol.43 (3), 329332. 10.1111/ced.13326

  • 64

    KentJ. W.Jr (2009). Analysis of Multiple Phenotypes. Genet. Epidemiol.33 (S1), S33S39. 10.1002/gepi.20470

  • 65

    Kjaersgaard AndersenR.ClemmensenS. B.LarsenL. A.HjelmborgJ. V. B.ØdumN.JemecG. B. E.et al (2021). Evidence of Gene-Gene Interaction in Hidradenitis Suppurativa: a Nationwide Registry Study of Danish Twins. Br. J. Dermatol.186 (1), 7885. 10.1111/bjd.20654

  • 66

    KopanosC.TsiolkasV.KourisA.ChappleC. E.Albarca AguileraM.MeyerR.et al (2019). VarSome: the Human Genomic Variant Search Engine. Bioinforma Oxf Engl.35 (11), 19781980. 10.1093/bioinformatics/bty897

  • 67

    KotzerkeM.MitriF.MarbachF.EnkA.HaenssleH. (2021). A Case of PAPASH Syndrome in a Young Man Carrying a Novel Heterozygote Missense Variant in PSTPIP1. J. Eur. Acad. Dermatol. Venereol.35 (7), e43940. 10.1111/jdv.17171

  • 68

    Kuemmerle-DeschnerJ. B.VermaD.EndresT.BroderickL.de JesusA. A.HoferF.et al (2017). Brief Report: Clinical and Molecular Phenotypes of Low-Penetrance Variants of NLRP3 : Diagnostic and Therapeutic Challenges. Arthritis Rheumatol.69 (11), 22332240. 10.1002/art.40208

  • 69

    LamiauxM.DabouzF.WantzM.LebasD.LasekA.CourivaudD.et al (2018). Successful Combined Antibiotic Therapy with Oral Clindamycin and Oral Rifampicin for Pyoderma Gangrenosum in Patient with PASH Syndrome. JAAD Case Rep.4 (1), 1721. 10.1016/j.jdcr.2017.05.005

  • 70

    LekM.KarczewskiK. J.MinikelE. V.SamochaK. E.BanksE.FennellT.et al (2016). Analysis of Protein-Coding Genetic Variation in 60,706 Humans. Nature536 (7616), 285291. 10.1038/nature19057

  • 71

    LeuenbergerM.BernerJ.Di LuccaJ.FischerL.KaparosN.ConradC.et al (2016). PASS Syndrome: An IL-1-Driven Autoinflammatory Disease. Dermatology232 (2), 254258. 10.1159/000443648

  • 72

    LiC.XuH.WangB. (2018). Is SAPHO Syndrome Linked to PASH Syndrome and Hidradenitis Suppurativa by Nicastrin Mutation? A Case Report. J. Rheumatol.45 (11), 16051607. 10.3899/jrheum.171007

  • 73

    LiC.-R.JiangM.-J.ShenD.-B.XuH.-X.WangH.-S.YaoX.et al (2011). Two Novel Mutations of the Nicastrin Gene in Chinese Patients with Acne Inversa. Br. J. Dermatol.165 (2), 415418. 10.1111/j.1365-2133.2011.10372.x

  • 74

    LiC.LiW.XuH.ZhangX.SuB.ZhangW.et al (2017). PSENEN Mutation Carriers with Co-manifestation of Acne Inversa (AI) and Dowling-Degos Disease (DDD): Is AI or DDD the Subphenotype?J. Invest. Dermatol.137 (10), 22342236. 10.1016/j.jid.2017.05.021

  • 75

    LiM.ChengR.LiangJ.YanH.ZhangH.YangL.et al (2013). Mutations in POFUT1, Encoding Protein O-Fucosyltransferase 1, Cause Generalized Dowling-Degos Disease. Am. J. Hum. Genet.92 (6), 895903. 10.1016/j.ajhg.2013.04.022

  • 76

    LinY.-Y.LinL.-H.KangJ.LiC.-R.XiaoX.-M. (2021). Hidradenitis Suppurativa Associated with a Novel NCSTN Mutation and Concomitant Klippel-Trenaunay Syndrome. Eur. J. Dermatol.31 (2), 246248. 10.1684/ejd.2021.4005

  • 77

    LiuM.DavisJ. W.IdlerK. B.MostafaN. M.OkunM. M.WaringJ. F. (2016). Genetic Analysis of NCSTN for Potential Association with Hidradenitis Suppurativa in Familial and Nonfamilial Patients. Br. J. Dermatol.175 (2), 414416. 10.1111/bjd.14482

  • 78

    LiuY.GaoM.LvY.-m.YangX.RenY.-q.JiangT.et al (2011). Confirmation by Exome Sequencing of the Pathogenic Role of NCSTN Mutations in Acne Inversa (Hidradenitis Suppurativa). J. Invest. Dermatol.131 (7), 15701572. 10.1038/jid.2011.62

  • 79

    Liy-WongC.KimM.KirkorianA. Y.EichenfieldL. F.DiazL. Z.HorevA.et al (2021). Hidradenitis Suppurativa in the Pediatric Population. JAMA Dermatol.157 (4), 385391. 10.1001/jamadermatol.2020.5435

  • 80

    LuP.BaiX.-c.MaD.XieT.YanC.SunL.et al (2014). Three-dimensional Structure of Human γ-secretase. Nature512 (7513), 166170. 10.1038/nature13567

  • 81

    MaS.YuY.YuG.ZhangF. (2014). Identification of One Novel Mutation of the NCSTN Gene in One Chinese Acne Inversa Family. Dermatologica Sinica32 (2), 126128. 10.1016/j.dsi.2013.06.003

  • 82

    MarzanoA. V.CeccheriniI.GattornoM.FanoniD.CaroliF.RusminiM.et al (2014). Association of Pyoderma Gangrenosum, Acne, and Suppurative Hidradenitis (PASH) Shares Genetic and Cytokine Profiles with Other Autoinflammatory Diseases. Medicine (Baltimore)93 (27), e187. 10.1097/md.0000000000000187

  • 83

    MarzanoA. V.GenoveseG.MoltrasioC.TricaricoP. M.GrattonR.PiasericoS.et al (2022). Whole-Exome Sequencing in 10 Unrelated Patients with Syndromic Hidradenitis Suppurativa: A Preliminary Step for a Genotype-Phenotype Correlation. Dermatology., 110. 10.1159/000521263

  • 84

    MarzanoA. V.TrevisanV.GattornoM.CeccheriniI.De SimoneC.CrostiC. (2013). Pyogenic Arthritis, Pyoderma Gangrenosum, Acne, and Hidradenitis Suppurativa (PAPASH): a New Autoinflammatory Syndrome Associated with a Novel Mutation of the PSTPIP1 Gene. JAMA Dermatol.149 (6), 762764. 10.1001/jamadermatol.2013.2907

  • 85

    McGrathJ. A. (2018). Concurrent Hidradenitis Suppurativa and Dowling-Degos Disease Taken Down a 'Notch'. Br. J. Dermatol.178 (2), 328. 10.1111/bjd.16068

  • 86

    MelnikB. C.PlewigG. (2013). Impaired Notch-MKP-1 Signalling in Hidradenitis Suppurativa: an Approach to Pathogenesis by Evidence from Translational Biology. Exp. Dermatol.22 (3), 172177. 10.1111/exd.12098

  • 87

    MintoffD.BorgI.PaceN. P. (2021a). The Clinical Relevance of the Microbiome in Hidradenitis Suppurativa: A Systematic Review. Vaccines9 (10), 1076. 10.3390/vaccines9101076

  • 88

    MintoffD.PaceN. P.BauerP.BorgI. (2021b). A novel c.671_682del NCSTN variant in a family with Hidradenitis Suppurativa: a pilot study. Clin. Exp. Dermatol.46 (7), 13061308. 10.1111/ced.14677

  • 89

    MintoffD.PaceN. P.BauerP.BorgI. (2021c). A novel c.671_682del NCSTN variant in a family with Hidradenitis Suppurativa: a pilot study. Clin. Exp. Dermatol.46, 1306. 10.1111/ced.14677

  • 90

    MiskinyteS.NassifA.MerabteneF.UngeheuerM.-N.Join-LambertO.JaisJ.-P.et al (2012). Nicastrin Mutations in French Families with Hidradenitis Suppurativa. J. Invest. Dermatol.132 (6), 17281730. 10.1038/jid.2012.23

  • 91

    MummJ. S.KopanR. (2000). Notch Signaling: From the outside in. Developmental Biol.228 (2), 151165. 10.1006/dbio.2000.9960

  • 92

    NikolakisG.KreibichK.VaiopoulosA.KaletaK.TalasJ.BeckerM.et al (2021). Case Report: PsAPSASH Syndrome: an Alternative Phenotype of Syndromic Hidradenitis Suppurativa Treated with the IL-17A Inhibitor Secukinumab. F1000Res10, 381. 10.12688/f1000research.52100.1

  • 93

    NishimoriN.HayamaK.KimuraK.FujitaH.FujiwaraK.TeruiT. (2020). A Novel NCSTN Gene Mutation in a Japanese Family with Hidradenitis Suppurativa. Acta Derm Venereol.100 (17), adv00283. 10.2340/00015555-3632

  • 94

    NivD.RamirezJ. A.FivensonD. P. (2017). Pyoderma Gangrenosum, Acne, and Hidradenitis Suppurativa (PASH) Syndrome with Recurrent Vasculitis. JAAD Case Rep.3 (1), 7073. 10.1016/j.jdcr.2016.11.006

  • 95

    NomuraT. (2020). Hidradenitis Suppurativa as a Potential Subtype of Autoinflammatory Keratinization Disease. Front. Immunol.11, 847. 10.3389/fimmu.2020.00847

  • 96

    NomuraY.NomuraT.SakaiK.SasakiK.OhguchiY.MizunoO.et al (2013). A Novel Splice Site Mutation inNCSTNunderlies a Japanese Family with Hidradenitis Suppurativa. Br. J. Dermatol.168 (1), 206209. 10.1111/j.1365-2133.2012.11174.x

  • 97

    NomuraY.NomuraT.SuzukiS.TakedaM.MizunoO.OhguchiY.et al (2014). A Novel NCSTN Mutation Alone May Be Insufficient for the Development of Familial Hidradenitis Suppurativa. J. Dermatol. Sci.74 (2), 180182. 10.1016/j.jdermsci.2014.01.013

  • 98

    OkuyamaR.TagamiH.AibaS. (2008). Notch Signaling: its Role in Epidermal Homeostasis and in the Pathogenesis of Skin Diseases. J. Dermatol. Sci.49 (3), 187194. 10.1016/j.jdermsci.2007.05.017

  • 99

    PanY.LinM.-H.TianX.ChengH.-T.GridleyT.ShenJ.et al (2004). γ-Secretase Functions through Notch Signaling to Maintain Skin Appendages but Is Not Required for Their Patterning or Initial Morphogenesis. Developmental Cell7 (5), 731743. 10.1016/j.devcel.2004.09.014

  • 100

    PavlovskyM.SarigO.Eskin-SchwartzM.MalchinN.BochnerR.MohamadJ.et al (2018). A Phenotype Combining Hidradenitis Suppurativa with Dowling-Degos Disease Caused by a Founder Mutation in PSENEN. Br. J. Dermatol.178 (2), e160. 10.1111/bjd.16285

  • 101

    PenhaR.Cortez de AlmeidaR. F.MarizJ.LisboaL.BarbosaL.da SilvaR. (2020). The Deregulation of NOTCH Pathway, Inflammatory Cytokines, and Keratinization Genes in Two Dowling-Degos Disease Patients with Hidradenitis Suppurativa. Am. J. Med. Genet.182 (11), 26622665. 10.1002/ajmg.a.61800

  • 102

    PeterD. C. V.SmithF. J. D.WilsonN. J.DandaS. (2021). PSENEN Mutation in Coexistent Hidradenitis Suppurativa and Dowling-Degos Disease. Indian Dermatol. Online J.12 (1), 147149. 10.4103/idoj.IDOJ_218_20

  • 103

    PinkA. E.DafouD.DesaiN.HolmesO.HobbsC.SmithC. H.et al (2016). Hidradenitis Suppurativa: Haploinsufficiency of Gamma-Secretase Components Does Not Affect Gamma-Secretase Enzyme Activityin Vitro. Br. J. Dermatol.175 (3), 632635. 10.1111/bjd.14621

  • 104

    PinkA. E.SimpsonM. A.BriceG. W.SmithC. H.DesaiN.MortimerP. S.et al (2011). PSENEN and NCSTN Mutations in Familial Hidradenitis Suppurativa (Acne Inversa). J. Invest. Dermatol.131 (7), 15681570. 10.1038/jid.2011.42

  • 105

    PinkA. E.SimpsonM. A.DesaiN.DafouD.HillsA.MortimerP.et al (2012). Mutations in the γ-Secretase Genes NCSTN , PSENEN , and PSEN1 Underlie Rare Forms of Hidradenitis Suppurativa (Acne Inversa). J. Invest. Dermatol.132 (10), 24592461. 10.1038/jid.2012.162

  • 106

    Plenary Lectures (2019). Plenary Lectures. Exp. Dermatol.28, 555. 10.1111/exd.13893

  • 107

    QianY-T.XiaoM.LiuK.MaD-L.ZhangX. (2021). Two Novel Mutations of the γ-secretase Genes in Chinese Acne Inversa (Hidradenitis Suppurativa). Exp. Dermatol.. 10.1111/exd.14496

  • 108

    RalserD. J.BasmanavF. B. Ü.TafazzoliA.WititsuwannakulJ.DelkerS.DandaS.et al (2017). Mutations in γ-secretase Subunit-Encoding PSENEN Underlie Dowling-Degos Disease Associated with Acne Inversa. J. Clin. Invest.127 (4), 14851490. 10.1172/jci90667

  • 109

    RatnamalaU.JhalaD.JainN. K.SaiyedN. M.RaveendrababuM.RaoM. V.et al (2016). Expanding the Spectrum Ofγ-Secretase Gene Mutation-Associated Phenotypes: Two Novel Mutations Segregating with Familial Hidradenitis Suppurativa (Acne Inversa) and Acne Conglobata. Exp. Dermatol.25 (4), 314316. 10.1111/exd.12911

  • 110

    RenJ.ZengL. Y. (2020). Scrotal Dowling-Degos Disease Caused by a Novel Frameshift Variant in Gamma-Secretase Subunit Presenile Enhancer Gene. Australas. J. Dermatol.61 (4), e399402. 10.1111/ajd.13316

  • 111

    RichardsS.AzizN.BaleS.BickD.DasS.Gastier-FosterJ.et al (2015). Standards and Guidelines for the Interpretation of Sequence Variants: a Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med.17 (5), 405424. 10.1038/gim.2015.30

  • 112

    RobinsonP. N. (2012). Deep Phenotyping for Precision Medicine. Hum. Mutat.33 (5), 777780. 10.1002/humu.22080

  • 113

    RodriguesC. H.PiresD. E.AscherD. B. (2018). DynaMut: Predicting the Impact of Mutations on Protein Conformation, Flexibility and Stability. Nucleic Acids Res.46 (W1), W350W355. 10.1093/nar/gky300

  • 114

    RooneyP.ConnollyM.GaoW.McCormickJ.BinieckaM.SullivanO.et al (2014). Notch-1 Mediates Endothelial Cell Activation and Invasion in Psoriasis. Exp. Dermatol.23 (2), 113118. 10.1111/exd.12306

  • 115

    SaitoN.Minami-HoriM.NagahataH.NozakiH.IinumaS.IgawaS.et al (2018). Novel PSTPIP1 Gene Mutation in Pyoderma Gangrenosum, Acne and Suppurative Hidradenitis Syndrome. J. Dermatol.45 (8), e213e214. 10.1111/1346-8138.14259

  • 116

    SakamotoK.JinS.-P.GoelS.JoJ.-H.VoisinB.KimD.et al (2021). Disruption of the Endopeptidase ADAM10-Notch Signaling axis Leads to Skin Dysbiosis and Innate Lymphoid Cell-Mediated Hair Follicle Destruction. Immunity54 (10), 23212337. 10.1016/j.immuni.2021.09.001

  • 117

    Saleh Al-AliF. M.RatnamalaU.MehtaT. Y.NaveedM.Al-AliM. T.Al-KhajaN.et al (2010). Hidradenitis Suppurativa (Or Acne Inversa) with Autosomal Dominant Inheritance Is Not Linked to Chromosome 1p21.1-1q25.3 Region. Exp. Dermatol.19 (9), 851853. 10.1111/j.1600-0625.2010.01088.x

  • 118

    SannerudR.EsselensC.EjsmontP.MatteraR.RochinL.TharkeshwarA. K.et al (2016). Restricted Location of PSEN2/γ-Secretase Determines Substrate Specificity and Generates an Intracellular Aβ Pool. Cell166 (1), 193208. 10.1016/j.cell.2016.05.020

  • 119

    SaracenoR.BabinoG.ChiricozziA.ZangrilliA.ChimentiS. (2015). PsAPASH: a New Syndrome Associated with Hidradenitis Suppurativa with Response to Tumor Necrosis Factor Inhibition. J. Am. Acad. Dermatol.72 (1), e42e44. 10.1016/j.jaad.2014.10.002

  • 120

    ShahS.LeeS.-F.TabuchiK.HaoY.-H.YuC.LaPlantQ.et al (2005). Nicastrin Functions as a γ-Secretase-Substrate Receptor. Cell122 (3), 435447. 10.1016/j.cell.2005.05.022

  • 121

    ShiT.-w.BaiN.ZhangJ.-a.LuF.ChenX.-b.KongX.-d.et al (2018). Mutations in the γ-secretase Genes PSEN1, PSENEN, and NCSTN in a Family with Acne Inversa. Eur. J. Dermatol. EJD28 (3), 374376. 10.1684/ejd.2018.3244

  • 122

    ShohamN. G.CentolaM.MansfieldE.HullK. M.WoodG.WiseC. A.et al (2003). Pyrin Binds the PSTPIP1/CD2BP1 Protein, Defining Familial Mediterranean Fever and PAPA Syndrome as Disorders in the Same Pathway. Proc. Natl. Acad. Sci. U.S.A.100 (23), 1350113506. 10.1073/pnas.2135380100

  • 123

    SkrozaN.MambrinA.TolinoE.BernardiniN.ProiettiI.AnzaloneA.et al (2019). A Case of Hidradenitis Suppurativa Linked to Trisomy 1q. J. Eur. Acad. Dermatol. Venereol.33 Suppl 6 (Suppl. 6), 3233. 10.1111/jdv.15824

  • 124

    StangaS.VrancxC.TasiauxB.MarinangeliC.KarlströmH.Kienlen‐CampardP. (2018). Specificity of Presenilin‐1‐ and Presenilin‐2‐dependent γ‐secretases towards Substrate Processing. J. Cell Mol Med22 (2), 823833. 10.1111/jcmm.13364

  • 125

    StarnesT. W.BenninD. A.BingX.EickhoffJ. C.GrahfD. C.BellakJ. M.et al (2014). The F-BAR Protein PSTPIP1 Controls Extracellular Matrix Degradation and Filopodia Formation in Macrophages. Blood123 (17), 27032714. 10.1182/blood-2013-07-516948

  • 126

    StaubJ.PfannschmidtN.StrohalR.Braun-FalcoM.LohseP.GoerdtS.et al (2015). Successful Treatment of PASH Syndrome with Infliximab, Cyclosporine and Dapsone. J. Eur. Acad. Dermatol. Venereol.29 (11), 22432247. 10.1111/jdv.12765

  • 127

    StephanC.KurbanM.AbbasO. (2021). Dowling‐Degos Disease: a Review. Int. J. Dermatol.60 (8), 944950. 10.1111/ijd.15385

  • 128

    StraalenK. R.PrensE. P.WillemsenG.BoomsmaD. I.ZeeH. (2020). Contribution of Genetics to the Susceptibility to Hidradenitis Suppurativa in a Large, Cross-Sectional Dutch Twin Cohort. JAMA Dermatol.156 (12), 13591362. 10.1001/jamadermatol.2020.3630[Internet] [cited 2020 Dec 6]; Available at: https://jamanetwork.com/journals/jamadermatology/fullarticle/2771622

  • 129

    SztalT. E.StainierD. Y. R. (2020). Transcriptional Adaptation: a Mechanism Underlying Genetic Robustness. Development147 (15), dev186452. 10.1242/dev.186452

  • 130

    TakeichiT.MatsumotoT.NomuraT.TakedaM.NiwaH.KonoM.et al (2020). A Novel NCSTN Missense Mutation in the Signal Peptide Domain Causes Hidradenitis Suppurativa, Which Has Features Characteristic of an Autoinflammatory Keratinization Disease. Br. J. Dermatol.182 (2), 491493. 10.1111/bjd.18445

  • 131

    ThéluJ.RossioP.FavierB. (2002). Notch Signalling Is Linked to Epidermal Cell Differentiation Level in Basal Cell Carcinoma, Psoriasis and Wound Healing. BMC Dermatol.2, 7. 10.1186/1471-5945-2-7

  • 132

    Theut RiisP.LoftI. C.YazdanyarS.Kjaersgaard AndersenR.PedersenO. B.RingH. C.et al (2020). Full Exome Sequencing of 11 Families with Hidradenitis Suppurativa. J. Eur. Acad. Dermatol. Venereol. JEADV35 (5), 12031211. 10.1111/jdv.17095

  • 133

    van StraalenK. R.VerhagenT.HorváthB.ArdonC.VossenA. R. J. V.DriessenR.et al (2018). Poor Interrater Reliability of Hidradenitis Suppurativa Phenotypes. J. Am. Acad. Dermatol.79 (3), 577578. 10.1016/j.jaad.2018.02.048

  • 134

    VasanthV.ChandrashekarB. (2014). Follicular Occlusion Tetrad. Indian Dermatol. Online J.5 (4), 491493. 10.4103/2229-5178.142517

  • 135

    VenselaarH.te BeekT. A.KuipersR. K.HekkelmanM. L.VriendG. (2010). Protein Structure Analysis of Mutations Causing Inheritable Diseases. An E-Science Approach with Life Scientist Friendly Interfaces. BMC Bioinformatics11 (1), 548. 10.1186/1471-2105-11-548

  • 136

    von LaffertM.StadieV.WohlrabJ.MarschW. C. (2011). Hidradenitis Suppurativa/acne Inversa: Bilocated Epithelial Hyperplasia with Very Different Sequelae. Br. J. Dermatol.164 (2), 367371. 10.1111/j.1365-2133.2010.10034.x

  • 137

    VossenA. R. J. V.van StraalenK. R.SwagemakersS. M. A.de KleinJ. E. M. M.StubbsA. P.VenterD. J.et al (2020a). A Novel Nicastrin Mutation in a Three-Generation Dutch Family with Hidradenitis Suppurativa: a Search for Functional Significance. J. Eur. Acad. Dermatol. Venereol. JEADV34 (10), 23532361. 10.1111/jdv.16310

  • 138

    VossenA. R. J. V.van StraalenK. R.SwagemakersS. M. A.de KleinJ. E. M. M.StubbsA. P.VenterD. J.et al (2020b). A Novel Nicastrin Mutation in a Three‐generation Dutch Family with Hidradenitis Suppurativa: a Search for Functional Significance. J. Eur. Acad. Dermatol. Venereol.34 (10), 23532361. 10.1111/jdv.16310

  • 139

    VuralS.BaumgartnerM.LichtnerP.EcksteinG.HariryH.ChenW. C.et al (2021). Investigation of Gamma Secretase Gene Complex Mutations in German Population with Hidradenitis Suppurativa Designate a Complex Polygenic Heritage. J. Eur. Acad. Dermatol. Venereol.35 (6), 13861392. 10.1111/jdv.17163

  • 140

    VuralS.GündoğduM.Gökpınar İliE.DurmazC. D.VuralA.Steinmüller‐MaginL.et al (2019). Association of Pyrin Mutations and Autoinflammation with Complex Phenotype Hidradenitis Suppurativa: a Case-Control Study. Br. J. Dermatol.180 (6), 14591467. 10.1111/bjd.17466

  • 141

    VuralS.GundogduM.KundakciN.RuzickaT. (2017). Familial Mediterranean Fever Patients with Hidradenitis Suppurativa. Int. J. Dermatol.56 (6), 660663. 10.1111/ijd.13503

  • 142

    WaiteA. L.SchanerP.RichardsN.Balci-PeynirciogluB.MastersS. L.BrydgesS. D.et al (2009). Pyrin Modulates the Intracellular Distribution of PSTPIP1. Plos One4 (7), e6147. 10.1371/journal.pone.0006147

  • 143

    WangB.YangW.WenW.SunJ.SuB.LiuB.et al (2010). γ-Secretase Gene Mutations in Familial Acne Inversa. Science330, 1065. 10.1126/science.1196284

  • 144

    WangX.PasolliH. A.WilliamsT.FuchsE. (2008). AP-2 Factors Act in Concert with Notch to Orchestrate Terminal Differentiation in Skin Epidermis. J. Cell Biol183 (1), 3748. 10.1083/jcb.200804030

  • 145

    WeberS.NiessenM. T.ProxJ.Lüllmann-RauchR.SchmitzA.SchwanbeckR.et al (2011). The Disintegrin/metalloproteinase Adam10 Is Essential for Epidermal Integrity and Notch-Mediated Signaling. Development138 (3), 495505. 10.1242/dev.055210

  • 146

    WigginsC. J.ChonS. Y. (2020). Cutaneous Effects of Notch Inhibitor Therapy: A Report of Two Cases. Case Rep. Dermatol. Med.2020, 8842242. 10.1155/2020/8842242

  • 147

    WilsonJ. J.KovallR. A. (2006). Crystal Structure of the CSL-Notch-Mastermind Ternary Complex Bound to DNA. Cell124 (5), 985996. 10.1016/j.cell.2006.01.035

  • 148

    Witte-HändelE.WolkK.TsaousiA.IrmerM. L.MößnerR.ShomroniO.et al (2019). The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction. J. Invest. Dermatol.139 (6), 12941305. 10.1016/j.jid.2018.11.018

  • 149

    WuC.YangJ.ZhangS.LiJ.JinH.ZhangX. (2018). A Novel NCSTN Gene Mutation in a Chinese Family with Acne Inversa. Mol. Genet. Genomics293 (6), 14691475. 10.1007/s00438-018-1475-9

  • 150

    WuJ.GeH.FanY.ZhenQ.TangL.SunL. (2020). Novel Mutation of the NCSTN Gene Identified in a Chinese Acne Inversa Family. Ann. Dermatol.32 (3), 237242. 10.5021/ad.2020.32.3.237

  • 151

    XiaoX.-M.ZhouP.-J.ZhuC.-H.LinL.-H.LiuJ.-J.HanY. (2020). Coexistence of Acne Inversa with Psoriasis and Dowling-Degos Disease Harboring Impaired PSENEN-Notch Signaling. Chin. Med. J. (Engl).133 (19), 23832385. 10.1097/cm9.0000000000001040

  • 152

    XiaoX.HeY.LiC.ZhangX.XuH.WangB. (2016). Nicastrin Mutations in Familial Acne Inversa Impact Keratinocyte Proliferation and Differentiation through the Notch and Phosphoinositide 3-kinase/AKT Signalling Pathways. Br. J. Dermatol.174 (3), 522532. 10.1111/bjd.14223

  • 153

    XiaoY. J.YangY.LiangY. H. (2018). hsa-miR-155 Targeted NCSTN 3'UTR Mutation Promotes the Pathogenesis and Development of Acne Inversa. Int. J. Clin. Exp. Pathol.11 (4), 18781889.

  • 154

    XieT.YanC.ZhouR.ZhaoY.SunL.YangG.et al (2014). Crystal Structure of the γ-secretase Component Nicastrin. Proc. Natl. Acad. Sci. U.S.A.111 (37), 1334913354. 10.1073/pnas.1414837111

  • 155

    XuH.XiaoX.HuiY.ZhangX.HeY.LiC.et al (2016). Phenotype of 53 Chinese Individuals with Nicastrin Gene Mutations in Association with Familial Hidradenitis Suppurativa (Acne Inversa). Br. J. Dermatol.174 (4), 927929. 10.1111/bjd.14268

  • 156

    YamamotoN.TanigakiK.HanH.HiaiH.HonjoT. (2003). Notch/RBP-J Signaling Regulates Epidermis/hair Fate Determination of Hair Follicular Stem Cells. Curr. Biol.13 (4), 333338. 10.1016/s0960-9822(03)00081-2

  • 157

    YuG.NishimuraM.ArawakaS.LevitanD.ZhangL.TandonA.et al (2000). Nicastrin Modulates Presenilin-Mediated Notch/glp-1 Signal Transduction and βAPP Processing. Nature407 (6800), 4854. 10.1038/35024009

  • 158

    YuJ.-W.Fernandes-AlnemriT.DattaP.WuJ.JulianaC.SolorzanoL.et al (2007). Pyrin Activates the ASC Pyroptosome in Response to Engagement by Autoinflammatory PSTPIP1 Mutants. Mol. Cell28 (2), 214227. 10.1016/j.molcel.2007.08.029

  • 159

    ZhangC.WangL.ChenL.RenW.MeiA.ChenX.et al (2013). Two Novel Mutations of the NCSTN Gene in Chinese Familial Acne Inverse. J. Eur. Acad. Dermatol. Venereol. JEADV27 (12), 15711574. 10.1111/j.1468-3083.2012.04627.x

  • 160

    ZhangX.HeY.XuH.WangB. (2020). First PSENEN Mutation in PASH Syndrome. J. Dermatol.47 (11), 13351337. 10.1111/1346-8138.15527

  • 161

    ZhangX.SisodiaS. S. (2015). Acne Inversa Caused by Missense Mutations in NCSTN Is Not Fully Compatible with Impairments in Notch Signaling. J. Invest. Dermatol.135 (2), 618620. 10.1038/jid.2014.399

  • 162

    ZhangX.SullivanE.ScimecaM.WuX.LiY.-m.SisodiaS. S. (2016). Evidence that the "Lid" Domain of Nicastrin Is Not Essential for Regulating γ-Secretase Activity. J. Biol. Chem.291 (13), 67486753. 10.1074/jbc.c115.701649

  • 163

    ZhangS.MengJ.JiangM.ZhaoJ. (2016). Characterization of a Novel Mutation in the NCSTN Gene in a Large Chinese Family with Acne Inversa. Acta Derm Venerol96 (3), 408409. 10.2340/00015555-2259

  • 164

    ZhangZ.ZhangB.GuoY.ChenJ.ZhengS.GaoX.et al (2021). A Novel Mutation of the NCSTN Gene in a Chinese Hidradenitis Suppurativa Family with Familial Comedones as the Main Clinical Manifestation. Int. J. Dermatol.10.1111/ijd.16021

  • 165

    ZhouP.LiuJ.XuT.GuoY.HanY.HeY.et al (2021). Mutations in γ-secretase Subunit-Encoding PSENEN Gene Alone May Not Be Sufficient for the Development of Acne Inversa. J. Dermatol. Sci.103 (21), 73001437300812. 10.1016/j.jdermsci.2021.06.007

  • 166

    ZhouC.WenG.-D.SoeL. M.XuH.-J.DuJ.ZhangJ.-Z. (2016). Novel Mutations in PSENEN Gene in Two Chinese Acne Inversa Families Manifested as Familial Multiple Comedones and Dowling-Degos Disease. Chin Med J (Engl).129 (23), 28342839. 10.4103/0366-6999.194648

  • 167

    ZhouX.EdmonsonM. N.WilkinsonM. R.PatelA.WuG.LiuY.et al (2016). Exploring Genomic Alteration in Pediatric Cancer Using ProteinPaint. Nat. Genet.48 (1), 46. 10.1038/ng.3466

  • 168

    ZouboulisC. C.MatusiakŁ.JemecG. B. E.SzepietowskiJ. C.Álvarez‐ChinchillaP. J.AsoskovaA.et al (2019). Inter‐rater and Intrarater Agreement and Reliability in Clinical Staging of Hidradenitis Suppurativa/acne Inversa. Br. J. Dermatol.181 (4), 852854. 10.1111/bjd.17982

Summary

Keywords

hidradenitis suppurativa, genetics, pathophysiology, gamma secretase (γ-secretase), familial

Citation

Pace NP, Mintoff D and Borg I (2022) The Genomic Architecture of Hidradenitis Suppurativa—A Systematic Review. Front. Genet. 13:861241. doi: 10.3389/fgene.2022.861241

Received

24 January 2022

Accepted

07 March 2022

Published

23 March 2022

Volume

13 - 2022

Edited by

Jared C Roach, Institute for Systems Biology (ISB), United States

Reviewed by

Chiara Moltrasio, IRCCS Ca ‘Granda Foundation Maggiore Policlinico Hospital, Italy

Marcelo Távora Mira, Pontifical Catholic University of Parana, Brazil

Updates

Copyright

*Correspondence: Nikolai Paul Pace,

† These authors share first authorship

This article was submitted to Human and Medical Genomics, a section of the journal Frontiers in Genetics

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics